

Table 2. Profiles of arterioles for occlusion before and after infusion of HbVs

Parameters	Before Infusion	After HbV Infusion	
		HbV ₈	HbV ₂₉
Arteriolar diameter, μm	53.0 ± 6.6	56.2 ± 6.8	55.8 ± 6.9
Centerline flow velocity, mm/s	3.1 ± 0.5	3.4 ± 0.7	3.5 ± 0.5
Blood flow rate, nl/s	6.8 ± 1.6	8.7 ± 3.1	8.5 ± 2.1
Arteriolar PO_2 , mmHg	50.7 ± 4.7	51.4 ± 4.8	52.1 ± 5.3
$\text{SaO}_2(\text{RBC})$, %	78.1 ± 5.1	76.0 ± 7.7	77.9 ± 6.5
$\text{SaO}_2(\text{HbV})$, %		$95.9 \pm 0.6^\dagger$	79.6 ± 4.7
O_2 content in whole blood, ml O_2/dl blood	18.61 ± 1.23	$20.30 \pm 1.18^*$	$20.17 \pm 1.54^*$
O_2 content in HbV, ml O_2/dl blood		1.51 ± 0.01	1.25 ± 0.07

Values are means \pm SD. Arteriolar PO_2 , O_2 saturation (SaO_2) and O_2 contents were obtained during 6 s before occlusion. * $P < 0.05$ vs. before infusion; $^\dagger P < 0.05$ vs. RBCs and HbV₂₉.

30-s occlusion, respectively. When the PO_2 values were expressed as relative to the baseline values (before occlusion), infusion of HbV₈ tended to show a slower rate of reduction of PO_2 compared with the infusion of HbV₂₉ and without infusion (Fig. 4). There was a significant difference between the HbV₈ infusion and before infusion groups only at 7 s ($P = 0.035$).




Fig. 3. Time course of PO_2 in the blood of an occluded arteriole (diameter, $53.0 \pm 6.6 \mu\text{m}$) before and after infusion of 7 ml/kg HbV₈ or HbV₂₉ into hamsters. Measurements were made in blood at a distance of 50 μm from the point of occlusion. Most vessels equilibrate to intravascular partial pressure in the range of 4–6 mmHg about 15–20 s after occlusion.




Fig. 4. Changes in PO_2 relative to before occlusion. The data in Fig. 3 were averaged. Baseline values before occlusion were obtained as the average of 6 values before occlusion and fixed as 1.0. There was a significant difference between the HbV₈ infusion and before infusion groups only at 7 s ($P = 0.035$).

$\text{SaO}_2(\text{RBC})$ and $\text{SaO}_2(\text{HbV})$ at every arteriolar PO_2 value can be estimated using the OECs in Fig. 1 assuming that the conditions in the arteriole (such as temperature and pH) do not change significantly from the normal condition (37°C, pH 7.4). Figure 5A shows the changes in the whole arteriolar O_2 content




Fig. 5. A: time course of the arteriolar O_2 content in whole blood of an occluded arteriole before and after infusion of 7 ml/kg HbV₈ or HbV₂₉ into hamsters. The O_2 contents were calculated using Eq. 2 and the data of OECs (Fig. 1) and PO_2 changes (Fig. 3). B: time course of the O_2 content derived from HbVs in the blood. The contributions of HbVs are derived from the data in A and magnified in scale. C: rate of O_2 loss $d\text{O}_2/dt$ from HbVs. The graphs in B were differentiated and plotted.

during the occlusion. Immediately after occlusion, the O_2 content decreased rapidly. The HbV₈ group showed a slower rate of reduction compared with the HbV₂₉ group and the group before HbV infusion. To demonstrate the contribution of HbVs clearly, only the O_2 content of HbVs is shown in Fig. 5B. HbV₈ showed a very slow rate of O_2 release. After 30 s of occlusion, the arteriolar P_{O_2} decreased to 5.2 ± 0.7 mmHg. However, $Sa_{O_2}(HbV_8)$ was $26.1 \pm 7.3\%$ and did not reach steady state but continued O_2 release. HbV₂₉ showed almost no change after 15 s, and $Sa_{O_2}(HbV_{29})$ was $7.4 \pm 1.0\%$ after 30 s. Figure 5C shows the rate of O_2 loss from HbVs obtained by the differentiation of the graphs in Fig. 5B. HbV₂₉ showed the fastest O_2 loss with the maximum of 0.18 ml O_2 /dl blood sec after only 2 s of occlusion and did not supply O_2 after 17 s. On the other hand, HbV₈ showed a moderate O_2 loss and showed the maximum of 0.08 ml O_2 /dl blood after 10 s of occlusion and continued to release O_2 until 30 s.

Figure 6 shows the fraction of O_2 in blood originating from HbVs. Before occlusion of the arterioles, the fractions of HbV₈ and HbV₂₉ are very small and similar because of the small dosage compared with the originally present RBCs. However, after occlusion, the fraction of O_2 from HbV₈ increased significantly and was about 0.55 after 10 s. This indicated that HbV₈, and not RBCs, was the main O_2 carrier when P_{O_2} attained very low values.

DISCUSSION

The principal finding of this study is that HbV₈ ($P_{50} = 8$ mmHg) with a high O_2 affinity (low P_{50}) releases O_2 at a slower rate than does HbV₂₉ in occluded arterioles of the hamster dorsal skinfold model. Furthermore, we found that HbV₈, and not HbV₂₉, is the main O_2 source in ischemic conditions.

The immediate occlusion of blood flow in the arterioles caused a rapid reduction of O_2 content. Similar phenomena have been observed by Richmond et al. (23) in rat spinotrapezius muscle tissue. There is substantial evidence that the arteriolar wall is a significant O_2 sink, consuming O_2 at a rate that is much greater than most tissues (9, 35, 42), which explains in part the significant and rapid drop of P_{O_2} found in our study. In our experiments, only one arteriole was occluded at a time in the intact subcutaneous tissue, and arteriolar P_{O_2} decreased to about 5 mmHg, which was higher than the critical P_{O_2} (2.9 ± 0.5 mmHg) in the rat spinotrapezius muscle tissue (23). Although the O_2 supply was significantly reduced, diffusion of O_2 from the other surrounding arterioles, venules, and

capillaries near the occlusion should contribute to maintaining tissue P_{O_2} at a higher value than in the study of Richmond et al. (23), where the supply of blood to the tissue was stopped altogether. $Sa_{O_2}(HbV_8)$ at 5 mmHg is estimated to be about 26% according to the OECs (Fig. 1), which is higher than that for HbV₂₉ (6%) and RBCs (2%); thus HbV₈ remains a source of O_2 for a longer period in a prolonged occlusion, because the fraction of O_2 from HbV₈ was 0.5 or higher, overwhelming the contribution from RBCs, as shown in Fig. 6.

A limitation of our experimental method is that Sa_{O_2} is estimated under the assumption that conditions in the target arteriole are identical to that of the OEC measurement; however, the O_2 affinity of Hb changes as a function of temperature, pH, electrolyte concentration, and CO_2 content. Local ischemic conditions caused by the occlusion could affect pH and increase CO_2 tension, resulting in a slight decrease in the O_2 affinity (increased P_{50}); however, it is unlikely that this would introduce a significant error in the measurement of O_2 release considering the short duration of the occlusion (30 s).

We have previously demonstrated using an artificial narrow polymer tube (inner diameter: 28 μ m) surrounded by a sodium dithionite solution to consume O_2 that a Hb solution under continuous flow conditions (1 mm/s) facilitates O_2 release when mixed with RBCs. Conversely, HbV did not show this phenomenon (31). This difference is due to the small size of O_2 -bound acellular Hb molecules, which diffuse and therefore contribute to the facilitated O_2 transport (21, 31), whereas HbVs (diameter, about 250 nm) are too large to show sufficient diffusion for the facilitated O_2 transport. In these conditions, O_2 affinity (P_{50}) becomes the determining factor for the rate of O_2 release and transport to the vessels wall. Thus, in our present results, the presence of HbVs did not facilitate the reduction of P_{O_2} or O_2 content but retarded the reduction of P_{O_2} and O_2 content.

Our experimental model is designed to characterize the O_2 release behavior of blood from an occluded microvessel and does not directly related to clinical ischemic conditions because the occlusion of the small arteriole for 30 s does not induce tissue ischemia other than the transient event in the proximity of the microvessel. However, our data suggest that HbV₈ could be a significant source of O_2 in an ischemic condition with significantly lowered tissue P_{O_2} . Because of the small dosage of HbV₈ (7 ml/kg), the O_2 content in the blood after occlusion (5 ml O_2 /dl blood at 5 s) is significantly smaller than the baseline value (20 ml O_2 /dl blood at 0 s). To enhance the contribution of HbVs, a larger dosage and sustained blood flow would be required. Contaldo et al. (7) recently demonstrated that inducing hemodilution using up to 50% blood exchange with HbV ($P_{50} = 15$ mmHg) suspended in dextran effectively oxygenated ischemic collateralized tissue in skin flaps. This phenomenon could be explained by low P_{50} HbVs retaining O_2 in the upstream vessels and delivering it to the ischemic tissue via collateral arterioles, even when these may have significantly slower blood flow. It has been proposed that small-sized HBOCs oxygenate ischemic tissue by being able to pass through constricted or partially occluded vessels that do not allow the passage of RBCs; however, the results from Contaldo et al. (17) as well as those from our experimental model do not serve to support this concept, because arterioles were completely ligated or occluded. It should be noted, however, that an advantage of small HBOCs, including HbVs,




Fig. 6. Time course of the fraction of O_2 content from HbVs in whole blood. The extended time of occlusion induced hypoxic conditions and the fraction of O_2 content from HbV₈ increased significantly compared with HbV₂₉.

is that they are homogeneously dispersed in the plasma phase and therefore can deliver O₂ more homogeneously to the periphery than RBCs because microvascular hematocrit is heterogeneous particularly in pathological states. In such conditions, HbVs with a higher O₂ affinity should show a slower O₂ unloading that would be effective for oxygenating ischemic tissues.

In conclusion, HbVs provide the unique feature of allowing for the regulation of P₅₀ by modulating the amount of coencapsulated PLP (33, 45). Recent studies showed the effectiveness of HBOCs with a lower P₅₀ (higher O₂ affinity) as a means of implementing O₂ delivery targeted to ischemic tissue (2, 3, 41, 43). Thus this experimental method provides data useful for the design and optimization of O₂ carriers and suggests the possible utilization of HbVs for therapeutic approaches aimed at remedying ischemic conditions.

ACKNOWLEDGMENTS

The authors greatly acknowledge A. Barra and C. Walser (University of California-San Diego) for help with the animal preparations, Dr. S. Takeoka and Dr. K. Sou (Waseda University) for the preparation of the HbVs, and Dr. D. Erni (Inselspital University Hospital, Bern, Switzerland) for meaningful discussions.

GRANTS

This study was supported in part by Health Sciences Research grants (Regulatory Science, Artificial Blood Project); the Ministry of Health, Labour and Welfare, Japan (H16-IYAKU-069, 071); Japan Society for the Promotion of Science Grant-In-Aid for Scientific Research B16300162; and National Heart, Lung, and Blood Institute Bioengineering Partnership Grant R24 HL-64395 and Grants R01 HL-40696 and R01 HL-62354. H. Sakai was an overseas research fellow of the Society of Japanese Pharmacopoeia.

REFERENCES

- Awasthi VD, Garcia D, Klipper R, Goins BA, and Phillips WT. Neutral and anionic liposome-encapsulated hemoglobin: effect of postinserted poly(ethylene glycol)-distearylphosphatidylethanolamine on distribution and circulation kinetics. *J Pharmacol Exp Ther* 309: 241–248, 2004.
- Baines AD, Adamson G, Wojciechowski P, Pliura D, Ho P, and Kluger R. Effect of modifying O₂ diffusivity and delivery on glomerular and tubular function in hypoxic perfused kidney. *Am J Physiol Renal Physiol* 274: F744–F752, 1998.
- Baines AD and Ho P. O₂ affinity of cross-linked hemoglobins modifies O₂ metabolism in proximal tubules. *J Appl Physiol* 95: 563–570, 2003.
- Buehler PW and Alayash AI. Toxicities of hemoglobin solutions: in search of in-vitro and in-vivo model systems. *Transfusion* 44: 1516–1530, 2004.
- Chang TMS. *Blood Substitutes: Principles, Methods, Products, and Clinical Trials*. Basel: Karger, 1997.
- Cabrera P, Sakai H, Tsai AG, Tsuchida E, and Intaglietta M. Oxygen transport by low and normal P₅₀ hemoglobin vesicles in extreme hemodilution. *Am J Physiol Heart Circ Physiol* 288: H1885–H1892, 2005. First published November 24, 2004; doi:10.1152/ajpheart.01004.2004.
- Contaldo C, Schramm S, Wettstein R, Sakai H, Takeoka S, Tsuchida E, Leunig M, Banic A, and Erni D. Improved oxygenation in ischemic hamster flap tissue is correlated with increasing hemodilution with Hb vesicles and their O₂ affinity. *Am J Physiol Heart Circ Physiol* 285: H1140–H1147, 2003.
- Djordjević L, Mayoral J, Miller IF, and Ivankovich AD. Cardio-respiratory effects of exchange transfusions with synthetic erythrocytes in rats. *Crit Care Med* 15: 318–323, 1987.
- Duling BR and Berne RM. Longitudinal gradients in periarteriolar oxygen tension. A possible mechanism for the participation of oxygen in the local regulation of blood flow. *Circ Res* 27: 669–678, 1970.
- Endrich B, Asaishi K, Gotz A, and Messmer K. Technical report: a new chamber technique for microvascular studies in unanesthetized hamsters. *Res Exp Med (Berl)* 177: 125–134, 1980.
- Erni D, Wettstein R, Schramm S, Sakai H, Takeoka S, Tsuchida E, Leunig M, and Banic A. Normovolemic hemodilution with hemoglobin-vesicle solution attenuates hypoxia in ischemic hamster flap tissue. *Am J Physiol Heart Circ Physiol* 284: H1702–H1709, 2003.
- Goda N, Suzuki K, Naito S, Takeoka S, Tsuchida E, Ishimura Y, Tamatani T, and Suematsu M. Distribution of heme oxygenase isoform in rat liver: topographic basis for carbon monoxide-mediated microvascular relaxation. *J Clin Invest* 101: 604–612, 1998.
- Intaglietta M, Johnson PC, and Winslow RM. Microvascular and tissue oxygen distribution. *Cardiovasc Res* 32: 632–643, 1996.
- Intaglietta M, Silverman NR, and Tompkins WR. Capillary flow velocity measurements in vivo and in situ by television methods. *Microvasc Res* 10: 165–179, 1975.
- Intaglietta M and Tompkins WR. Microvascular measurements by video image shearing and splitting. *Microvasc Res* 5: 309–312, 1973.
- Izumi Y, Sakai H, Hamada K, Takeoka S, Yamahata Y, Kato R, Nishide H, Tsuchida E, and Kobayashi K. Physiologic responses to exchange transfusion with hemoglobin vesicles as an artificial oxygen carrier in anesthetized rats: changes in mean arterial pressure and renal cortical tissue oxygen tension. *Crit Care Med* 24: 1869–1873, 1996.
- Kerger H, Torres Filho IP, Rivas M, Winslow RM, and Intaglietta M. Systemic and subcutaneous microvascular oxygen tension in conscious Syrian golden hamsters. *Am J Physiol Heart Circ Physiol* 268: H802–H810, 1995.
- Kyokane Norimuzu S T, Tani H, Yamaguchi T, Takeoka S, Tsuchida E, Naito M, Nimura Y, Ishimura Y, and Suematsu M. Carbon monoxide from heme catabolism protects against hepatobiliary dysfunction in endotoxin-treated rat liver. *Gastroenterology* 120: 1227–1240, 2001.
- Linberg R, Conover CD, Shum KL, and Shorr RGL. Increased tissue oxygenation and enhanced radiation sensitivity of solid tumors in rodents following polyethylene glycol conjugated bovine hemoglobin administration. *In Vivo* 12: 167–174, 1998.
- Lipowsky HH and Zweifach B. Application of the “two slit” photometric technique to the measurement of microvascular volumetric flow rates. *Microvasc Res* 15: 93–101, 1978.
- McCarthy MR, Vandegeriff KD, and Winslow RM. The role of facilitated diffusion in oxygen transport by cell-free hemoglobins: implications for the design of hemoglobin-based oxygen carriers. *Biophys Chem* 92: 103–117, 2001.
- Papenfuss HD, Gross JF, Intaglietta M, and Treese FA. A transparent access chamber for the rat dorsal skin fold. *Microvasc Res* 18: 311–318, 1979.
- Richmond KN, Shonat RD, Lynch RM, and Johnson PC. Critical P_{O₂} of skeletal muscle in vivo. *Am J Physiol Heart Circ Physiol* 277: H1831–H1840, 1999.
- Rudolph AS, Klipper RW, Goins B, and Phillips WT. In vivo biodistribution of a radiolabelled blood substitute: ^{99m}Tc-labeled liposome-encapsulated hemoglobin in an anesthetized rabbit. *Proc Natl Acad Sci USA* 88: 10976–10980, 1991.
- Sakai H, Hara H, Tsai AG, Tsuchida E, Johnson PC, and Intaglietta M. Changes in resistance vessels during hemorrhagic shock and resuscitation in conscious hamster model. *Am J Physiol Heart Circ Physiol* 276: H563–H571, 1999.
- Sakai H, Hara H, Yuasa M, Tsai AG, Takeoka S, Tsuchida E, and Intaglietta M. Molecular dimensions of Hb-based O₂ carriers determine constriction of resistance arteries and hypertension in conscious hamster model. *Am J Physiol Heart Circ Physiol* 279: H908–H915, 2000.
- Sakai H, Hisamoto S, Fukutomi I, Sou K, Takeoka S, and Tsuchida E. Detection of lipopolysaccharide in hemoglobin-vesicles by *Limulus amoebocyte* lysate test with kinetic-turbidimetric gell clotting analysis and pretreatment with a surfactant. *J Pharm Sci* 93: 310–321, 2004.
- Sakai H, Horinouchi H, Tomiyama K, Ikeda E, Takeoka S, Kobayashi K, and Tsuchida E. Hemoglobin-vesicles as oxygen carriers: influence on phagocytic activity and histopathological changes in reticuloendothelial systems. *Am J Pathol* 159: 1079–1088, 2001.
- Sakai H, Masada Y, Horinouchi H, Ikeda E, Sou K, Takeoka S, Suematsu M, Kobayashi K, and Tsuchida E. Physiologic capacity of reticuloendothelial system for degradation of hemoglobin-vesicles (artificial oxygen carriers) after massive intravenous doses by daily repeated infusion for 14 days. *J Pharmacol Exp Ther* 311: 874–884, 2004.
- Sakai H, Masada Y, Horinouchi H, Yamamoto M, Ikeda E, Takeoka S, Kobayashi K, and Tsuchida E. Hemoglobin-vesicles suspended in recombinant human serum albumin for resuscitation from hemorrhagic shock in anesthetized rats. *Crit Care Med* 32: 539–545, 2004.

31. Sakai H, Suzuki Y, Kinoshita M, Takeoka S, Maeda N, and Tsuchida E. O₂-release from Hb-vesicles evaluated using an artificial narrow O₂-permeable tube: comparison with RBC and acellular Hb. *Am J Physiol Heart Circ Physiol* 285: H2543–H2551, 2003.
32. Sakai H, Takeoka S, Yokohama H, Seino Y, Nishide H, and Tsuchida E. Purification of concentrated Hb using organic solvent and heat treatment. *Protein Expr Purif* 4: 563–569, 1993.
33. Sakai H, Tsai AG, Rohlfis RJ, Hara H, Takeoka S, Tsuchida E, and Intaglietta M. Microvascular responses to hemodilution with Hb-vesicles as red blood cell substitutes: influences of O₂ affinity. *Am J Physiol Heart Circ Physiol* 276: H553–H562, 1999.
34. Sakai H, Yuasa M, Onuma H, Takeoka S, and Tsuchida E. Synthesis and physicochemical characterization of a series of hemoglobin-based oxygen carriers: objective comparison between cellular and acellular types. *Bioconjug Chem* 11: 56–64, 2000.
35. Shibata M, Ichioka S, Ando J, and Kamiya A. Microvascular and interstitial PO₂ measurements in rat skeletal muscle by phosphorescence quenching. *J Appl Physiol* 91: 321–327, 2001.
36. Shirasawa T, Izumizaki M, Suzuki YI, Ishihara A, Shimizu T, Tamaki M, Huang F, Koizumi KI, Iwase M, Sakai H, Tsuchida E, Ueshima U, Inoue H, Koseki H, Senda H, Kuriyama T, and Homma I. Oxygen affinity of hemoglobin regulates O₂ consumption, metabolism, and physical activity. *J Biol Chem* 278: 5035–5043, 2003.
37. Sou K, Naito Y, Endo T, Takeoka S, and Tsuchida E. Effective encapsulation of proteins into size-controlled phospholipid vesicles using freeze-thawing and extrusion. *Biotechnol Progr* 19: 1547–1552, 2003.
38. Takeoka S, Teramura Y, Atoji T, and Tsuchida E. Effect of Hb-encapsulation with vesicles on H₂O₂ reaction and lipid peroxidation. *Bioconjug Chem* 13: 1302–1308, 2002.
39. Tomson FN and Wardrop KJ. Clinical chemistry and hematology. In: *Laboratory Hamsters*, edited by van Hoosier GL Jr and McPherson CW. Orlando, FL: Academic, 1987, chapt. 3, p. 43–59.
40. Torres Filho IP and Intaglietta M. Microvascular PO₂ measurements by phosphorescence decay method. *Am J Physiol Heart Circ Physiol* 265: H1434–H1438, 1993.
41. Tsai AG, Kerger H, and Intaglietta M. Microcirculatory consequences of blood substitution with $\alpha\alpha$ -hemoglobin. In: *Blood Substitutes: Physiological Basis of Efficacy*, edited by Winslow RM, Vandegriff K, and Intaglietta M. Boston, MA: Birkhauser, 1995, p. 155–174.
42. Tsai AG, Friesenecker B, Mazzoni MC, Kerger H, Buerk DG, Johnson PC, and Intaglietta M. Microvascular and tissue oxygen gradients in the rat mesentery. *Proc Natl Acad Sci USA* 95: 6590–6595, 1998.
43. Tsai AG, Vandegriff KD, Intaglietta M, and Winslow RM. Targeted O₂ delivery by low-P₅₀ hemoglobin: a new basis for O₂ therapeutics. *Am J Physiol Heart Circ Physiol* 285: H1411–H1419, 2003.
44. Vanderkooi JM, Maniara G, Green TJ, and Wilson DF. An optical method for measurement of dioxygen concentration based on quenching of phosphorescence. *J Biol Chem* 262: 5476–5482, 1987.
45. Wang L, Morizawa K, Tokuyama S, Satoh T, and Tsuchida E. Modulation of oxygen-carrying capacity of artificial red cells (ARC). *Polymer Adv Technol* 4: 8–11, 1992.



New generation of hemoglobin-based oxygen carriers evaluated for oxygenation of critically ischemic hamster flap tissue

Claudio Contaldo, MD; Jan Plock, MD; Hiromi Sakai, PhD; Shinji Takeoka, PhD; Eishun Tsuchida, PhD; Michael Leunig, MD; Andrej Banic, MD, PhD; Dominique Erni, MD

Objectives: The aim of this study was to investigate and compare the effects of a traditionally formulated, low-viscosity, right-shifted polymerized bovine hemoglobin solution and a highly viscous, left-shifted hemoglobin vesicle solution (HbV-HES) on the oxygenation of critically ischemic peripheral tissue.

Design: Randomized, prospective study.

Setting: University laboratory.

Subject: A total of 40 male golden Syrian hamsters.

Interventions: Island flaps were dissected from the back skin of anesthetized hamsters. The flap included a critically ischemic, hypoxic area that was perfused via a collateralized vasculature. One hour after completion of the preparation, the animals received a 33% blood exchange with 6% hydroxyethyl starch 200/0.5 (HES, n = 9), HbV suspended in HES (HbV-HES, n = 8), or polymerized bovine hemoglobin solution (n = 9).

Measurements and Main Results: Three hours after the blood exchange, microcirculatory blood flow (laser-Doppler flowmetry) was increased to 262% of baseline for HbV-HES ($p < .01$) and

197% for polymerized bovine hemoglobin solution ($p < .05$ vs. baseline and HbV-HES). Partial tissue oxygen tension (bare fiber probes) was only improved after HbV-HES (9.4 torr to 14.2 torr, $p < .01$ vs. baseline and other groups). The tissue lactate/pyruvate ratio (microdialysis) was elevated to 51 in the untreated control animals, and to 34 ± 8 after HbV-HES ($p < .05$ vs. control) and 38 ± 11 after polymerized bovine hemoglobin solution (not significant).

Conclusions: Our study suggests that in critically ischemic and hypoxic collateralized peripheral tissue, oxygenation may be improved by normovolemic hemodilution with HbV-HES. We attributed this improvement to a better restoration of the microcirculation and oxygen delivery due to the formulation of the solution. (Crit Care Med 2005; 33:806–812)

KEY WORDS: arterial occlusive diseases; blood substitutes; collateral circulation; energy metabolism; microcirculation; surgical flaps

Occlusion of the anatomic blood supply may lead to critical ischemia in a variety of organs and tissues. Functionality and survival of these tissues depend on the maintenance of adequate oxygen delivery via a collateral vasculature, which is determined by its perfusion and oxygen content.

Artificial oxygen carriers, first developed >30 yrs ago, were created to increase the oxygen content of arterialized blood without risking the adverse effects associated with blood transfusions (1–3). These products were designed to meet the physicochemical properties of normal blood as closely as possible. However, a number of drawbacks have hindered their introduction into clinical practice. One major problem was the vasoconstrictor effect of cell-free hemoglobins, presumably due to their scavenging of nitric oxide (NO) (1–3). This adverse effect has been circumvented by chemical modification of the hemoglobin molecules. Hemopure (Biopure, Cambridge, MA) is one of two chemically modified hemoglobin products currently awaiting U.S. Food and Drug Administration approval after having been extensively tested in clinical trials as a replacement for blood transfusions (4). Hemopure has been approved for routine clinical use in South Africa. Oxyglobin, its veterinary equivalent, was introduced to the U.S. market in 1998. It is a polyionic colloidal

fluid consisting of glutaraldehyde-polymerized, ultrapurified bovine hemoglobin (PBHb) suspended in a modified Ringer's solution. Oxyglobin contains 13 g/dL hemoglobin (Table 1). Hemoglobin concentration, osmolarity, and viscosity are in a physiologic range, whereas colloid osmotic pressure was set higher and oxygen affinity was right-shifted ($P_{50} = 54$ torr) (5) with the scope of blood volume expansion and facilitated oxygen release.

In past years, a new concept has emerged in which oxygen carriers are regarded as oxygen therapeutics rather than as blood substitutes (2, 3, 5–8). Still, in an attempt to avoid blood transfusions, the new generation of artificial oxygen carriers are used to improve the microcirculation and redistribute oxygen in favor of the tissues in need without necessarily augmenting total hemoglobin concentration. For this purpose, increased colloid osmotic pressure, viscosity, and oxygen affinity of the oxygen-carrying solutions proved to be advantageous and more relevant than

From the Department of Orthopedic, Plastic, and Hand Surgery, Inselspital University Hospital, Berne, Switzerland (CC, JP, ML, AB, DE); and the Advanced Research Institute for Science and Engineering, Waseda University, Tokyo, Japan (HS, ST, ET).

Supported, in part, by the Swiss National Foundation for Scientific Research (grants 32-054092.98 and 32-065149.01 to D. Erni and grant 32-050771.97 to M. Leunig); the Department of Clinical Research, University of Berne, Switzerland; a grant for Health Sciences Research (Research on Pharmaceutical and Medical Safety, Artificial Blood Project) from the Ministry of Health, Labour, and Welfare, Japan; and by Grants in Aid for Scientific Research from the Japanese Society for the Promotion of Science (B16300162).

Copyright © 2005 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins

DOI: 10.1097/01.CCM.0000159195.12111.CE

Table 1. Physicochemical characteristics of hamster blood and the diluents

	Hamster Blood	Hamster Plasma	HES	HbV-HES	PBHb
Hb concentration, g/dL	18		0	7.5	13
Mean particle diameter, nm	7,000			250	10
Mean molecular mass, kDa				3,000,000	180
P ₅₀ , torr	28			15	54
metHb concentration, %				5.2	5.0
Oncotic pressure, mm Hg		18	36	36	38
Viscosity of solution, cP	4.5	1.2	1.9	11.5	1.8
Viscosity in circulation, cP		1.34	1.31	1.68 ^a	1.42 ^{a,b}

HES, 6% hydroxyethyl starch; HbV-HES, hemoglobin vesicles suspended in HES; PBHb, polymerized bovine hemoglobin; Hb, hemoglobin; metHb, methemoglobin.

^a*p* < .01 vs. hamster plasma; ^b*p* < .01 vs. HbV-HES. Viscosity of the solutions was measured at 37°C and at 150 s⁻¹; plasma viscosity was measured at 25°C; data are mean values.

raising the hemoglobin concentration in blood, as evidenced by a series of experimental shock studies (5, 7, 8). It seems conceivable that the concept of targeting oxygen delivery to ischemic tissues may be particularly applicable in an acute situation of local tissue ischemia due to peripheral arterial occlusion, serving as a bridge until adequate perfusion can be re-established either by spontaneous neovascularization or surgical revascularization. In previous studies, we were able to demonstrate that oxygenation in collateralized, ischemic hamster flap tissue was improved after isovolemic hemodilution with highly viscous, highly oncotic solutions containing left-shifted, encapsulated human hemoglobins (9, 10). Encapsulation represents a new alternative to chemical modification and was achieved by a phospholipid bilayer membrane coated with polyethylene glycol (11).

The aim of this study was to compare the effects of a traditionally formulated polymerized bovine hemoglobin solution (Oxyglobin) and a highly viscous solution containing a low concentration of left-shifted encapsulated hemoglobins (the new generation of oxygen carriers), both administered in the course of intentional isovolemic hemodilution, on the oxygenation of acutely and critically ischemic peripheral tissues in the well-established

hamster-flap model described previously (9, 10, 12). Due to its widespread clinical use, hydroxyethyl starch (HES) was chosen as the diluent in which the encapsulated hemoglobins (hemoglobin vesicles, HbV) were suspended. Microcirculatory blood flow, partial tissue oxygen tension, tissue lactate concentration, and lactate/pyruvate ratio were taken as end points.

Table 2. Systemic and laboratory data at baseline and at 1 and 3 hrs after blood exchange

	Baseline	1 hr	3 hrs
MAP, mm Hg			
Control	91 ± 6	90 ± 5	83 ± 11 ^a
HES	93 ± 6	92 ± 6	84 ± 7 ^a
HbV-HES	94 ± 3	92 ± 3	80 ± 7 ^b
PBHb	95 ± 5	92 ± 3	93 ± 6
Hematocrit			
Control	0.55 ± 0.04	0.54 ± 0.03	0.52 ± 0.03
HES	0.59 ± 0.04	0.31 ± 0.04 ^b	0.31 ± 0.04 ^b
HbV-HES	0.59 ± 0.04	0.31 ± 0.02 ^b	0.33 ± 0.04 ^b
PBHb	0.58 ± 0.05	0.32 ± 0.05 ^b	0.31 ± 0.04 ^b
Total Hb concentration, g/dL			
Control	17.8 ± 1.2	17.2 ± 1.0	17.0 ± 1.1
HES	17.8 ± 1.3	9.7 ± 0.9 ^b	10.5 ± 1.0 ^b
HbV-HES	18.8 ± 0.7	11.2 ± 1.3 ^b	12.1 ± 1.0 ^b
PBHb	18.0 ± 1.8	13.6 ± 0.9 ^b	11.9 ± 1.1 ^b
Po ₂ , torr			
Control	43 ± 3	44 ± 6	43 ± 4
HES	43 ± 13	56 ± 10	64 ± 13 ^b
HbV-HES	43 ± 4	51 ± 13	68 ± 9 ^b
PBHb	43 ± 8	53 ± 9	61 ± 11 ^b
Pco ₂ , torr			
Control	58 ± 8	58 ± 9	56 ± 8
HES	57 ± 3	56 ± 3	47 ± 13 ^a
HbV-HES	53 ± 4	51 ± 4	41 ± 3 ^b
PBHb	57 ± 5	53 ± 4 ^a	47 ± 5 ^b
pH			
Control	7.28 ± 0.06	7.29 ± 0.06	7.29 ± 0.06
HES	7.23 ± 0.03	7.27 ± 0.03 ^a	7.31 ± 0.07 ^b
HbV-HES	7.27 ± 0.03	7.30 ± 0.03 ^a	7.34 ± 0.02 ^b
PBHb	7.25 ± 0.02	7.30 ± 0.05 ^a	7.34 ± 0.06 ^b

MAP, mean arterial pressure; HES, 6% hydroxyethyl starch; HbV-HES, hemoglobin vesicles suspended in HES; PBHb, polymerized bovine hemoglobin.

^a*p* < .05 and ^b*p* < .01 vs. baseline. Values displayed as mean ± SD.




Figure 1. Diagram illustrating sequence of interventions.

MATERIALS AND METHODS

Animals and Solutions. Experiments were performed according to the National Institutes of Health guidelines for the care and use of laboratory animals and with the approval of the local animal ethics committee. A total of 40 male Syrian golden hamsters (Charles River, Sulzfeld, Germany) weighing 75–110 g were included in this study. The animals were randomly assigned and equally distributed to the control group and three groups subjected to normovolemic hemodilution with 6% HES 200/0.5 (Fresenius, Stans, Switzerland), HbV suspended in HES (HbV-HES), and PBHb, respectively. HbV was prepared as described previously (11). PBHb (Oxyglobin) was purchased from Biopure. The physicochemical characteristics of the solutions are described in Table 1.

Animal and Flap Preparation. A hamster skin-flap model was used as previously described in detail (9, 10, 12). Anesthesia was induced by pentobarbital injected intraperitoneally (100 mg/kg body weight, Nembutal, Abbott Laboratories, Chicago, IL). The carotid artery and external jugular vein were cannulated for administration of anesthesia, blood exchange, laboratory analysis, and monitoring blood pressure. Catheterization and flap dissection were performed with the aid of an

Table 3. Microvascular diameters (in micrometers) at baseline

	Control	HES	HbV-HES	PBHb
Flap artery	112 ± 15	122 ± 18	114 ± 8	118 ± 17
Anatomically perfused tissue				
Conduit arterioles	57 ± 8	58 ± 14	54 ± 12	56 ± 15
End arterioles	8.4 ± 3.2	8.9 ± 3.4	7.7 ± 2.7	7.8 ± 2.3
Ischemic tissue				
Conduit arterioles	56 ± 9	54 ± 15	60 ± 10	54 ± 17
End arterioles	8.4 ± 3.2	8.9 ± 3.4	7.7 ± 2.7	7.8 ± 2.3

HES, 6% hydroxyethyl starch; HbV-HES, hemoglobin vesicles suspended in HES; PBHb, polymerized bovine hemoglobin.

Values are mean ± SD.




Figure 2. Microvascular diameters in flap artery, conduit arterioles, and end arterioles in the anatomically perfused and ischemic tissues at baseline (BL) and after hemodilution with 6% hydroxyethyl starch (HES), hemoglobin vesicles suspended in HES (HbV-HES), and polymerized bovine hemoglobin (PBHb). Data are given as a percentage of baseline and represent mean values and SD. * $p < .05$, ** $p < .01$ vs. baseline; ° $p < .05$, °° $p < .01$ vs. control; # $p < .05$ vs. HbV-HES.

by one vascular axis that bifurcated into two equal-sized branches within the flap, each of them supplying a separate vascular territory. One of the branches was transected after being secured with microsurgical ligatures, thus rendering the corresponding vascular territory ischemic. This tissue was perfused by a collateral vasculature connecting the two vascular networks. During surgery, the flap was irrigated with 0.9% NaCl to prevent the flap from drying out. The animal was placed on a specially designed Plexiglas stage including a platform for fixation of the flap.

Laboratory Analysis. Blood samples were taken from the carotid artery catheter and collected in heparin-washed microtubes for immediate measurements of total hemoglobin concentration, pH and systemic arterial P_{O_2} and P_{CO_2} (ABL 625, Radiometer, Copenhagen, Denmark). Hematocrit was determined by centrifugation. The colloid osmotic pressure of the diluents was measured with a colloid osmometer (model 4420, Wescor, Logan, UT) with a 30,000 d cutoff membrane. The viscosity was measured with a cone-plate viscometer (PVII+, Brookfield Engineering, Middleboro, MA) or a capillary rheometer (Anton Parr DCS 300, Parr Physica, Graz, Austria) at 37°C. Viscosity of blood and plasma were measured 3 hrs after hemodilution with a Höppler-type viscosimeter (HAAKE Messtechnik, Karlsruhe, Germany).

Microhemodynamics and Partial Tissue Oxygen Tension. Investigations were performed using an intravital microscope (Axio-plan 1, Zeiss, Jena, Germany). Microscopic images were captured by a television camera (Intensified CCD camera, Kappa Messtechnik, Gleichen, Germany), recorded on video (50 Hz, Panasonic, Osaka, Japan), and displayed on a television screen (Trinitron PVM-1454QM, Sony, Tokyo, Japan). The preparation was observed visually with a ×40 objective resulting in a total optical magnification of ×909 on the video monitor. Transilluminating with a green filter produced a well-defined image of the width of the erythrocyte column, which could then be measured manually on the television screen. A mapping of the vasculature was made before the baseline measurements were taken to allow for repeated measurements of diameters on exactly the same vessel and location. The arterioles were classified according to physiologic and anatomic features into conduit arterioles and end arterioles (9, 10, 12).

We used combined bare fiber probes (Oxy-lite probes, Oxford Optronix, Oxford, UK) to measure tissue oxygen tension, temperature, and microvascular blood flow continuously. Microvascular blood flow was measured with two 230- μ m fibers. The sensitive tip of the oxygen probe (100 μ m in diameter) consisted of Ruthenium-III-(tris)-chloride, which measured P_{O_2} by fluorescence quenching of the dye. A T-type thermocouple was attached to the probe, which was coated with a biocompatible sleeve of polyurethane. According to

operating microscope at ×10 magnification (Wild, Heerbrugg, Switzerland). An island flap measuring 3 × 2 cm was dissected from the

shaved and epilated back skin of the animal. The flap consisted of skin and a thin layer of panniculus carnosus muscle and was perfused




Figure 3. Microcirculatory blood flow in the anatomically perfused and ischemic tissues at baseline (BL) and after hemodilution with 6% hydroxyethyl starch (HES), hemoglobin vesicles suspended in HES (HbV-HES), and polymerized bovine hemoglobin (PBHb). Data are given as a percentage of baseline and represent mean values and SD. * $p < .05$, ** $p < .01$ vs. baseline and control; # $p < .05$ vs. HbV-HES.

the manufacturer, the bare fiber probe provides resolutions of <1 torr and 0.1°C for partial oxygen tension and temperature, respectively. The data on blood flow were displayed in arbitrary perfusion units and further processed into percentages of the baseline.

Carbohydrate Metabolite Concentrations. The interstitial concentrations of glucose, pyruvate, and lactate were assessed by microdialysis, as previously described (13, 14). The system used in our study included microprobes (CMA/20, CMA Microdialysis AB, Stockholm, Sweden) carrying a microcell that was perfused by a microinjection pump (CMA/100, CMA Microdialysis AB). The molecular cutoff of the membrane was 20,000 d. This pore size does not allow the tested Hb compounds to penetrate into the microcell, as confirmed by preliminary pilot experiments. The outlet tube was connected to a refrigerated fraction collector (CMA/200 F, CMA Microdialysis AB) in which the dialysates were collected in microvials, stored at 4°C , and further processed for laboratory analysis (CMA 600, CMA Microdialysis AB). The microcell was continuously

perfused with isotonic Ringer's solution at a flow rate of $0.75 \mu\text{L}/\text{min}$, which resulted in a time delay from the membrane to the microvial of 7 mins. The sampling time was set at 60 mins. Before each experiment, the probes were equilibrated according to the guidelines of the supplier.

Protocol. The animals were kept under light anesthesia with a continuous infusion of $50 \text{ mg}/\text{mL}$ pentobarbital given at a rate of approximately $0.5 \text{ mg}\cdot\text{min}^{-1}\cdot\text{kg}$ body weight $^{-1}$ throughout the experiment. The depth of anesthesia was regulated by tolerating a noxious reflex due to pinching of the hind paw, but no nonaversive reflexes (palpebral, corneal, and jaw reflex) (12). With a heating pad and the room's temperature at 28°C , the temperatures of the animals were kept constant at 32°C , which was verified with a microthermometer placed on the abdominal skin.

Microdialysis and Oxylite probes were inserted subcutaneously in the middle of each vascular territory of the flap. The timing of the interventions is illustrated in Figure 1. The

collection of the microdialysates started after a 30-min stabilization period. Another hour later, the baseline values were obtained. Thereafter, one third of the total blood volume was exchanged with HES or the oxygen-carrying solutions. This was achieved by simultaneous blood withdrawal via the carotid catheter and infusion via the jugular catheter over 15 mins. Exclusion criteria were abnormalities of the vascular anatomy, insufficient optical clarity, mean arterial pressure of <60 mm Hg, and systemic arterial pH, Po_2 , and Pco_2 outside the normal ranges at baseline (7.19–7.29, 35–55 torr, and 45–65 torr, respectively). The animals were killed with an overdose of pentobarbital at the end of the experiment.

Statistical Analysis. The InStat version 3 program (Graph Pad Software, San Diego, CA) was used for statistical analysis. The data were presented as mean \pm SD. The time-related differences between repeat measurements were assessed by the paired analysis of variance, followed by the Dunnett's posttest. Differences between the groups were assessed by unpaired analysis of variance and Tukey's posttest. A value of $p < .05$ was taken to represent statistical significance.

RESULTS

Six animals (two control animals, one in the HES group, two in the HbV-HES group, and one in the PBHb group) did not fulfill the inclusion criteria and were excluded from this study. The systemic data are presented in Table 2. Mean arterial pressure gradually declined during the experiment in all groups ($p < .05$) except the Oxyglobin group, in which mean arterial pressure remained virtually unchanged ($p < .05$ vs. other groups). Similar hematocrits were obtained in all hemodiluted animals. After the 33% blood exchange with HES, Hb concentration was reduced to $9.7 \pm 0.9 \text{ g}/\text{dL}$, whereas the addition of HbV to the diluent enhanced the total Hb concentration to $11.2 \pm 1.3 \text{ g}/\text{dL}$ ($p < .05$ vs. HES), and hemodilution with PBHb resulted in a total Hb concentration of $13.6 \pm 0.9 \text{ g}/\text{dL}$ ($p < .05$ vs. HbV-HES). However, this difference became less pronounced over time. Hemodilution increased mean Po_2 from 43 torr to mean values of >60 torr and mean pH from 7.23–7.27 to mean values of 7.31–7.34, whereas mean Pco_2 decreased from 53–57 torr to 41–47 torr (all $p < .01$ vs. baseline).

At baseline, the microvascular diameters were similar in all groups (Table 3). The behaviors of the microvascular diameters are shown in Figure 2. The diameters were gradually reduced over time in




Figure 4. P_{O_2} in the anatomically perfused and ischemic tissues at baseline (BL) and after hemodilution with 6% hydroxyethyl starch (HES), hemoglobin vesicles suspended in HES (HbV-HES), and polymerized bovine hemoglobin (PBHb). Data represent mean values and SD. ** $p < .01$ vs. baseline and control; # $p < .05$, ## $p < .01$ vs. HbV-HES.

the flap artery in all animals (not significant for HES, $p < .01$ for other groups) but most substantially in the PBHb group, where they reached $76\% \pm 7\%$ of baseline ($p < .01$ vs. control, $p < .05$ vs. HbV-HES). In the anatomically perfused tissue, diameters were decreased to $79\% \pm 7\%$ in the conduit arterioles ($p < .01$ vs. baseline and control, $p < .05$ vs. HbV-HES) and $85\% \pm 8\%$ ($p < .01$ vs. baseline) in the end arterioles after receiving PBHb, whereas no significant differences were observed between the other groups. A similar yet less pronounced pattern was seen in the collateralized arterioles ($p < .01$ vs. baseline for PBHb).

The mean baseline laser-Doppler signals ranged between 61 and 114 perfusion units in the anatomically perfused

tissue and between 3 and 17 perfusion units in the ischemic part. Microcirculatory blood flow remained virtually unchanged in the anatomically perfused tissue in all groups (Fig. 3), whereas mean blood flow was maximally increased after hemodilution by 168% for HES ($p < .01$), 170% for HbV-HES ($p < .01$), and 100% for PBHb ($p < .05$ vs. baseline and HbV-HES).

Oxygen tension was significantly reduced in the ischemic tissue compared with the anatomically perfused part ($p < .01$) (Fig. 4). It remained at baseline levels in both parts of the flap and in all groups except for HbV-HES, which showed a P_{O_2} increase from 9.4 ± 2.5 torr to 14.2 ± 4.5 torr in the ischemic tissue ($p < .01$ vs. baseline and other groups).

Glucose concentrations were gradually decreased in the anatomically perfused tissue over time (Fig. 5), reaching 1.5 ± 1.1 mmol/L in the control group ($p < .01$), 2.7 ± 1.2 mmol/L for HES (not significant), 3.1 ± 1.4 mmol/L for HbV-HES (not significant, $p < .05$ vs. control), and 2.2 ± 0.9 mmol/L for PBHb ($p < .01$). The reductions were more accentuated in the ischemic tissue, at 0.8 ± 0.6 mmol/L in the control group ($p < .01$), 1.4 ± 0.9 mmol/L in the HES group ($p < .01$), 1.6 ± 1.4 mmol/L in the HbV-HES group (not significant), and 1.3 ± 0.7 mmol/L in the PBHb group ($p < .01$). At baseline, the mean lactate concentrations ranged between 1.7 and 2.2 mmol/L in both parts of the tissue in all groups. The values remained virtually stable in the anatomically perfused tissue. In the ischemic tissue, lactate concentrations were raised to 2.8 ± 0.6 mmol/L in control ($p < .01$) and to 3.4 ± 1.4 mmol/L in HES ($p < .01$) but only to 2.4 ± 1.0 mmol/L in HbV-HES and to 2.2 ± 0.7 mmol/L in PBHb (both not significant). At baseline, the mean lactate/pyruvate ratio was higher in the ischemic tissue (24–27) compared with the anatomic part (19–22). No relevant changes occurred in the anatomic part. Lactate/pyruvate ratio was increased to 51 ± 23 in the control group and 48 ± 12 in the HES group (both $p < .01$) but only to 34 ± 8 and 38 ± 11 for HbV-HES (not significant vs. baseline, $p < .05$ vs. control) and PBHb ($p < .05$), respectively.

DISCUSSION

The principal findings of this study were that the elevation in lactate concentration and lactate/pyruvate ratio in the critically ischemic tissue could be attenuated by isovolemic hemodilution with the oxygen-carrying solutions. This suggests that oxidative energy metabolism was improved in the hypoxic cells, which is crucial for their survival and functional outcome. The effect was superior for HbV-HES, which also yielded markedly higher oxygen tension in the ischemic flap tissue. Both tissue oxygen tension and oxidative energy metabolism are dependent on the oxygen supply to this tissue, which is determined by the oxygen content of the blood entering the collateralized tissue and the perfusion of the latter.

As expected, microcirculatory blood flow was substantially improved in all hemodiluted animals due to the hematocrit reduction; however, microcirculatory blood flow was improved to a lesser ex-




Figure 5. Carbohydrate metabolite concentrations in the anatomically perfused and ischemic tissues at baseline (BL) and after hemodilution with 6% hydroxyethyl starch (HES), hemoglobin vesicles suspended in HES (HbV-HES), and polymerized bovine hemoglobin (PBHb). Data represent mean values and SD. * $p < .05$, ** $p < .01$ vs. baseline; ° $p < .05$ vs. control.

tent for PBHb, which also yielded diminished microvascular diameters. In previous studies we demonstrated that microvascular blood flow and diameter were closely related to the rheologic formulation of the diluent, thus advocating solutions with both high colloid osmotic pressure and high viscosity (9).

The colloid osmotic pressure of the solutions used in the present study was approximately twice as high as that of hamster plasma, thus causing volume expansion, as evidenced by hematocrit values that were markedly lower than the theoretical value expected after a normovolemic 33% blood exchange. The volume expansion was similar for both oxygen-carrying solutions, whereas he-

modilution with HbV-HES resulted in markedly higher viscosity in the plasma phase. Plasma viscosity affects shear stress on the vascular lining, thus stimulating the NO-mediated relaxation of the vascular tone in small arteries and large arterioles (15). NO may be scavenged by cell-free hemoglobin, which may cause a strong vasopressor effect and subsequent hypertension (1, 16). It has been shown that the degree of NO-scavenging is correlated with the size of the hemoglobin compound (16), the HbV being more than ten times larger than the PBHb. NO-scavenging was most likely the reason for the microvascular narrowing found after the administration of PBHb in our study. This vasoconstriction was

Our study suggests that in critically ischemic and hypoxic collateralized peripheral tissue, oxygenation may be improved by normovolemic hemodilution with hemoglobin vesicles suspended in hydroxyethyl starch.

most pronounced in the flap artery. This vascular segment was considered most sensitive to NO-mediated regulation of vascular tone (17) and vasopressor effect of acellular hemoglobins (16), which may explain the higher mean arterial pressure we obtained in the animals receiving PBHb compared with HbV-HES. Taken together, our data suggest that HbV-HES provides a better balance of oxygen carrier-related viscosity increase and NO-scavenging.

However, the prevention of metabolic deterioration in the ischemic flap tissue after hemodilution with the oxygen-carrying solutions cannot be solely related to the improved microcirculatory blood flow because no metabolic benefit was observed in the animals receiving HES. One possible explanation is that due to their small size, the supplemented hemoglobins may perfuse capillaries that are no longer accessible by red blood cells and that are therefore relieved of their function. Although not measured in this study, impaired functional capillary density, a common feature in the compromised microcirculation (5, 7, 18), must be assumed in the ischemic flap tissue. Indeed, circulating HbVs were observed in capillaries showing a cessation of red blood cell flux (18).

The improved oxygen tension found in the ischemic tissue after hemodilution with HbV-HES is indicative of a larger amount of oxygen being brought to the collateralized vasculature than is the case with the PBHb group. According to the oxygen dissociation curve for hamster blood (5, 19), hemodilution with both oxygen-carrying solutions led to an in-

crease in arterial oxygen saturation of the cellular hemoglobin from approximately 80% at baseline to 90% at 3 hrs after blood exchange, whereas the estimated oxygen saturation was approximately 95% for the HbV but only 60% for PBHb, thus resulting in a slightly higher arterial oxygen content in the HbV-HES animals. Furthermore, it may be postulated that HbVs prevented the transmural diffusion of oxygen during the passage through the upstream vasculature. This mechanism may influence oxygen delivery to collateralized tissues substantially, because up to 40–50% of the systemic arterial oxygen was estimated to be lost from the upstream circulation before reaching the collateral vasculature nourishing the ischemic flap tissue (12). Upstream oxygen loss may be influenced in many ways by the addition of oxygen-carrying solutions. According to the Stokes-Einstein equation, the diffusivity of oxygen through the plasma is inversely proportional to the size of the plasma-bound oxygen carrier and the viscosity of the suspension, which were both greater for HbV-HES. Facilitated diffusion has been reported for PBHbs in static (20) and dynamic (21) *in vitro* models, whereas virtually no such effect has been obtained with HbVs (20, 22). Enhancing the oxygen affinity of the added oxygen carrier shifts transmural oxygen diffusion downstream, as has repeatedly been demonstrated *in vivo* (5, 19), *in vitro* (22), and in mathematical models (23). In a recent study, we were able to show that the oxygenation in the critically ischemic hamster flap tissue could substantially be improved by left-shifting of the HbV (10). Taken together, it may be assumed that with HbV-HES, there was less unwanted oxygen loss in the upstream vasculature before reaching the collateralized, ischemic flap tissue than with PBHb. This was likely due to the larger size of HbV-HES, the higher oxygen affinity of its hemoglobin compound, and the higher viscosity of the solution.

CONCLUSIONS

From our data, we conclude that hypoxia in the critically ischemic hamster flap tissue was substantially attenuated

after hemodilution with HbV-HES and PBHb due to improved microcirculation and the presence of the supplemented oxygen carriers. It seemed that due to its rheologic formulation and physiochemical properties, HbV-HES provided a superior oxygen supply to the ischemic flap tissue. Therefore, our data suggest that the concept of targeting oxygen delivery to where it is most needed may find a particular, clinically most relevant application in the treatment of hypoxia in critically ischemic peripheral tissues. However, these findings may not be extrapolated to vital organs. Moreover, the beneficial effect obtained with the artificial oxygen carriers may be further enhanced by adding antioxidant enzymes to attenuate any possible ischemia-reperfusion injury (1).

REFERENCES

- Chang TM: Artificial cells for cell and organ replacements. *Artif Organs* 2004; 28:265–270
- Jahr JS, Nesargi SB, Lewis K, et al: Blood substitutes and oxygen therapeutics: An overview and current status. *Am J Ther* 2002; 9:437–443
- Winslow RM: Current status of blood substitute research: Towards a new paradigm. *J Intern Med* 2003; 253:508–517
- Sprung J, Kindscher JD, Wahr JA, et al: The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: Results of a multicenter, randomized, single-blinded trial. *Anesth Analg* 2002; 94:799–808
- Tsai AG, Vandegriff KD, Intaglietta M, et al: Targeted O₂ delivery by low-P50 hemoglobin: A new basis for O₂ therapeutics. *Am J Physiol* 2003; 285:H1411–H1419
- Intaglietta M: Microcirculatory basis for the design of artificial blood. *Microcirculation* 1999; 6:247–258
- Wettstein R, Tsai AG, Erni D, et al: Resuscitation with polyethylene glycol-modified human hemoglobin improves microcirculatory blood flow and tissue oxygenation after hemorrhagic shock in awake hamsters. *Crit Care Med* 2003; 31:1882–1884
- Winslow RM, Gonzales A, Gonzales ML, et al: Vascular resistance and the efficacy of red cell substitutes in a rat hemorrhage model. *J Appl Physiol* 1998; 85:993–1003
- Erni D, Wettstein R, Schramm S, et al: Normovolemic hemodilution with Hb vesicle solution attenuates hypoxia in ischemic hamster flap tissue. *Am J Physiol* 2003; 284: H1702–H1709
- Contaldo C, Schramm S, Wettstein R, et al: Improved oxygenation in ischemic hamster flap tissue is correlated with increasing hemodilution with Hb vesicles and their O₂ affinity. *Am J Physiol* 2003; 285:H1140–H1147
- Sakai H, Takeoka S, Park SI, et al: Surface modification of hemoglobin vesicles with poly(ethyleneglycol) and effects on aggregation, viscosity, and blood flow during 90% exchange transfusion in anesthetized rats. *Bioconj Chem* 1997; 8:15–22
- Erni D, Sakai H, Tsai AG, et al: Haemodynamics and oxygen tension in the microcirculation of ischaemic skin flaps after neural blockade and haemodilution. *Br J Plast Surg* 1999; 52:565–572
- Ungerstedt U: Microdialysis: Principles and applications for studies in animals and man. *J Intern Med* 1991; 230:365–373
- Harris AG, Schropp A, Schütze E, et al: Implementation of the microdialysis method in the hamster dorsal skinfold chamber. *Res Exp Med* 1999; 199:141–152
- Kuo L, Davis MJ, Chilian WM: Endothelial modulation of arteriolar tone. *News Physiol Sci* 1992; 7:5–9
- Sakai H, Hara H, Yuasa M, et al: Molecular dimensions of Hb-based O₂ carriers determine constriction of resistance arteries and hypertension. *Am J Physiol* 2000; 279:H908–H915
- Sakai H, Hara H, Tsai AG, et al: Constriction of resistance arteries determines l-NAME-induced hypertension in a conscious hamster model. *Microvasc Res* 2000; 60:21–27
- Sakai H, Takeoka S, Wettstein R, et al: Systemic and microvascular responses to hemorrhagic shock and resuscitation with Hb vesicles. *Am J Physiol* 2002; 283:H1191–H1199
- Sakai H, Tsai AG, Rohlf's RJ, et al: Microvascular response to hemodilution with Hb vesicles as red blood cell substitutes: Influence of O₂ affinity. *Am J Physiol* 1999; 276: H552–H562
- Nishide H, Chen XS, Tsuchida E: Facilitated oxygen transport with modified and encapsulated hemoglobins across non-flowing solution membrane. *Artif Cells Blood Substitut Immobil Biotechnol* 1997; 25:335–346
- Page TC, Light WR, McKay CB, et al: Oxygen transport by erythrocyte/hemoglobin solution mixtures in an *in vitro* capillary as a model of hemoglobin-based oxygen carrier performance. *Microvasc Res* 1998; 55:54–64
- Sakai H, Suzuki Y, Kinoshita M, et al: O₂-release from Hb-vesicles evaluated using an artificial narrow O₂-permeable tube: Comparison with RBC and acellular Hb. *Am J Physiol* 2003; 285:H2543–H2551
- Vadapalli A, Goldman D, Popel AS: Calculations of oxygen transport by red blood cells and hemoglobin solutions in capillaries. *Artif Cells Blood Substitut Immobil Biotechnol* 2002; 30:157–188

Oxygen transport by low and normal oxygen affinity hemoglobin vesicles in extreme hemodilution

Pedro Cabrales,^{1,2} Hiromi Sakai,³ Amy G. Tsai,^{1,2}
Shinji Takeoka,³ Eishun Tsuchida,³ and Marcos Intaglietta^{1,2}

¹Department of Bioengineering, University of California-San Diego, and ²La Jolla Bioengineering Institute, La Jolla, California; and ³Advanced Research Institute for Science and Engineering, Waseda University, Tokyo, Japan

Submitted 1 October 2004; accepted in final form 18 November 2004

Cabrales, Pedro, Hiromi Sakai, Amy G. Tsai, Shinji Takeoka, Eishun Tsuchida, and Marcos Intaglietta. Oxygen transport by low and normal oxygen affinity hemoglobin vesicles in extreme hemodilution. *Am J Physiol Heart Circ Physiol* 288: H1885–H1892, 2005. First published November 24, 2004; doi:10.1152/ajpheart.01004.2004.—The oxygen transport capacity of phospholipid vesicles encapsulating purified Hb (HbV) produced with a P_{O_2} at which Hb is 50% saturated (P_{50}) of 8 (HbV₈) and 29 mmHg (HbV₂₉) was investigated in the hamster chamber window model by using microvascular measurements to determine oxygen delivery during extreme hemodilution. Two isovolemic hemodilution steps were performed with 5% recombinant albumin (rHSA) until Hct was 35% of baseline. Isovolemic exchange was continued using HbV suspended in rHSA solution to a total [Hb] of 5.7 g/dl in blood. P_{50} was modified by coencapsulating pyridoxal 5'-phosphate. Final Hct was 11% for the HbV groups, with a plasma [Hb] of 2.1 ± 0.1 g/dl after exchange with HbV₈ or HbV₂₉. A reference group was hemodiluted to Hct 11% with only rHSA. All groups showed stable blood pressure and heart rate. Arterial oxygen tensions were significantly higher than baseline for the HbV groups and the rHSA group and significantly lower for the HbV groups compared with the rHSA group. Blood pressure was significantly higher for the HbV₈ group compared with the HbV₂₉ group. Arteriolar and venular blood flows were significantly higher than baseline for the HbV groups. Microvascular oxygen delivery and extraction were similar for the HbV groups but lower for the rHSA group ($P < 0.05$). Venular and tissue P_{O_2} were statistically higher for the HbV₈ vs. the HbV₂₉ and rHSA groups ($P < 0.05$). Improved tissue P_{O_2} is obtained when red blood cells deliver oxygen in combination with a high- rather than low-affinity oxygen carrier.

oxygen-carrying capacity; blood substitutes; tissue oxygen; hemoglobin oxygen affinity

PHOSPHOLIPID VESICLES encapsulating concentrated hemoglobin (Hb) solution [Hb vesicles (HbV) or liposome-encapsulated Hb] provide oxygen-carrying capacity to plasma expanders, reproducing several of the characteristics of red blood cells (RBC) suspended in plasma. HbV contain Hb at a high concentration within a cell membrane-like structure. Their oxygen dissociation curve can be adjusted by varying the concentration of pyridoxal 5'-phosphate (PLP). A widely accepted premise for designing a blood substitute is that its Hb should have an oxygen dissociation curve like that of RBC or one that is right shifted, i.e., having a high P_{50} to facilitate the unloading of oxygen (P_{50} is the partial pressure of oxygen at which the Hb molecule is 50% saturated). In a previous study by Sakai et al. (16), vesicles were formulated with P_{50} values set at 9, 16, and

30 mmHg. The study showed that optimal tissue oxygen conditions were obtained when 80% of the circulating blood was substituted with HbV whose P_{50} was 16 mmHg, a value considerably lower than the usual value of 28 mmHg for normal blood (16). Oxygen-carrying capacity was found to be well above the oxygen supply limitation.

Recent developments in the field of oxygen-carrying plasma expanders (OCPE) based on molecular Hb solutions reported by Tsai et al. (22) show that the addition of comparatively small amounts of a significantly left-shifted polyethylene glycol-conjugated oxygen carrier ($P_{50} \sim 5$ mmHg) to blood in extreme hemodilution leads to baseline microvascular and systemic conditions. This result could not be obtained in identical extreme hemodilution experiments with the use of a right-shifted molecular Hb solution at a considerably higher concentration (19).

Extreme hemodilution in the hamster window chamber model to a hematocrit (Hct) level of $\sim 11\%$ is a powerful tool to test the efficacy of OCPEs in restoring microvascular function and systemic conditions. This Hct is below the threshold at which the organism becomes oxygen supply limited (5, 22, 23). In this scenario, the effects of a blood substitute became magnified upon introduction into the circulation. Furthermore, by encapsulating Hb, a phospholipid vesicle eliminates the problem of Hb extravasation and provides a setting in which the biophysical properties of the infusion solution can be rigorously controlled while allowing for the change in P_{50} . Therefore, experimenting with vesicles that encapsulate Hb formulated with different P_{50} values provides the unique opportunity to investigate how oxygen affinity regulates oxygen delivery to the tissue by the microcirculation, a value not attainable by lowering RBC Hb P_{50} by the administration of sodium cyanate, which may introduce changes in tissue metabolism (7). In addition, RBC and HbV are different in size, flow pattern, homogeneous distribution in the plasma phase, and the mechanism of oxygen unloading in capillaries, and direct comparison between RBC and HbV is impossible. All these conditions indicate that the optimal P_{50} should be different in HbV and RBC.

In the present study, we investigated the microvascular effects of restoring oxygen-carrying capacity in conditions of extreme hemodilution, introducing by exchange transfusion identical amounts of Hb-carrying vesicles in which oxygen affinity was specifically controlled so that P_{50} was either 8 or 29 mmHg. The P_{50} value of 8 mmHg was chosen because it is

Address for reprint requests and other correspondence: P. Cabrales, Dept. of Bioengineering, 0412, 9500 Gilman Dr., Univ. of California-San Diego, La Jolla, CA 92093-0412 (E-mail: pcabrales@ucsd.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

similar to that of a recently developed oxygen carrier that is effective at a low concentration (2–4, 22). In these experiments, the hemodilution protocols were performed using a recombinant albumin solution (13) as the plasma expander.

METHODS

Investigations were performed in male golden Syrian hamsters (55–65 g body wt) fitted with a dorsal skinfold chamber window (6). This model has been used extensively for investigations of the intact microvasculature of adipose and subcutaneous tissue and skeletal muscle in conscious animals for extended periods. Pentobarbital sodium (50 mg/kg ip) was used for window implantation and for carotid artery and jugular vein catheterization. The microvasculature was examined 4–5 days after the initial surgery, and only animals passing an established systemic and microcirculatory inclusion criteria, which included having tissue void of low perfusion, inflammation, and edema (21), were entered into the study. Animal handling and care followed the NIH *Guide for the Care and Use of Laboratory Animals*. The experimental protocol was approved by the local animal care committee.

Preparation of HbV with different P_{50} . HbV were prepared under sterile conditions as previously reported (12, 15). Hb was purified from outdated donated blood provided by the Hokkaido Red Cross Blood Center (Sapporo, Japan) and the Japanese Red Cross Society (Tokyo, Japan). The encapsulated purified Hb (38 g/dl) contained 0 or 14.7 mM PLP (Sigma Chemical, St. Louis, MO) as an allosteric effector at a molar ratio of [PLP]/[Hb] = 0 or 2.5, respectively. The lipid bilayer was composed of a mixture of 1,2-dipalmitoyl-*sn*-glycero-3-phosphatidylcholine, cholesterol, and 1,5-bis-*O*-hexadecyl-*N*-succinyl-L-glutamate at a molar ratio of 5:5:1 (Nippon Fine Chemical, Osaka, Japan) and 1,2-distearoyl-*sn*-glycero-3-phosphatidylethanolamine-*N*-poly(ethylene glycol) (0.3 mol% of the total lipid; NOF, Tokyo, Japan) (17). HbV with a 250-nm diameter were suspended in a physiological saline solution in which [Hb] = 10 g/dl, sterilized with filters (Dismic, pore size 0.45 μ m; Toyo Roshi, Tokyo, Japan), and deoxygenated with N₂ bubbling for storage (14). The content of lipopolysaccharide was <0.1 EU/ml.

Before use, the HbV suspension ([Hb] = 10 g/dl, 8.6 ml) was mixed with a solution of recombinant human serum albumin (rHSA 25%, 1.4 ml; Nipro, Osaka, Japan) to regulate the rHSA concentration in the suspending medium of the vesicles to 5 g/dl. Under this condition, the colloid osmotic pressure of the suspension is ~20 mmHg (Wescor 4420 colloid osmometer; Wescor, Logan, UT) (12). As a result, the Hb concentration of the suspension was 8.6 g/dl.

In a previous study (16), HbV were suspended in 8 g/dl HSA. However, we changed to 5 g/dl rHSA because it showed better microvascular perfusion in the hamster window model (i.e., increased red cell velocity and functional capillary density) than 8 g/dl HSA. The suspension was filtered through sterile filters (pore size 0.45 μ m; Millipore, Billerica, MA). The characteristics of HbV are listed in Table 1, with all parameters being almost identical except oxygen affinity (HbV₈, P_{50} = 8 mmHg; HbV₂₉, P_{50} = 29 mmHg).

Table 1. Physical characteristics of solutions

Fluid	Viscosity, cp	COP, mmHg	P_{50} , mmHg
rHSA (5%)	0.98	20	
HbV ₈ (10 g Hb/dl)	2.92		8
HbV ₂₉ (10 g Hb/dl)	2.96		29
HbV ₈ /rHSA (8.6 g Hb/dl)	2.87	20	8
HbV ₂₉ /rHSA (8.6 g Hb/dl)	2.90	20	29

Viscosity was measured at a shear rate of 160 s⁻¹ at 37°C. COP, colloid osmotic pressure measured at 27°C; P_{50} , partial pressure of oxygen at which Hb is 50% saturated; rHSA, recombinant human serum albumin; HbV₈ and HbV₂₉, Hb vesicles with a P_{50} of 8 and 29 mmHg, respectively.




Fig. 1. Oxygen dissociation curves for phospholipid vesicles encapsulating purified Hb (HbV) produced with a P_{O_2} at which Hb is 50% saturated (P_{50}) of 8 (HbV₈) and 29 mmHg (HbV₂₉) vs. the dissociation curve for hamster blood (P_{50} = 32 mmHg).

Measurements of P_{50} and rate of oxygen release from HbV. The P_{50} and Hill number of each HbV and Hb solution were calculated from oxygen dissociation curves measured with a Hemox analyzer (TCS-Medical Products) at 37°C (Fig. 1).

Acute isovolemic exchange-transfusion (hemodilution) protocol. Progressive hemodilution to a final systemic Hct level of 11% was accomplished with three isovolemic exchange steps. This protocol, leading to extreme hemodilution while maintaining stable hemodynamic conditions, is described in detail in a previous report by Tsai (19). Briefly, the volume of each exchange-transfusion step was calculated as a percentage of the blood volume, estimated as 7% of the body weight. An acute anemic state was induced by lowering systemic Hct by 60% with two steps of progressive isovolemic hemodilution using 5% rHSA, referred to as exchange levels 1 and 2. Level 1 exchange was 40% of blood volume, and level 2 and 3 exchanges were 35% of blood volume, respectively.

After level 2, the animals were randomly divided into three experimental groups by being assigned to an experimental group according to a sorting scheme based on a list of random numbers (1). Level 2 exchange was followed by level 3 exchange. Hemodilution with 5% rHSA solution was continued with one group of the level 2 hemodiluted animals, the experimental group rHSA, until Hct was decreased to 11% of baseline (Fig. 2). The test materials were studied by assigning the remainder of the level 2 animals to groups labeled HbV₈ (P_{50} = 8 mmHg) and HbV₂₉ (P_{50} = 29 mmHg) and were hemodiluted using these materials, reducing Hct to 11%. Plasma Hb concentrations derived for HbV₈ and HbV₂₉ after exchange of 35% blood volume are estimated around 2.0–2.3 g/dl for both groups (35% of estimated total Hb content) (21).

Because mixed blood is withdrawn during the exchanges, a 110% blood volume exchange was needed to reduce Hct to 25% of baseline (11% Hct). Test solutions were infused into the jugular vein catheter after passing through an in-line, 13-mm-diameter, 0.2- μ m syringe filter at a rate of 100 μ l/min. Blood was simultaneously withdrawn using a dual syringe pump ("33" syringe pump; Harvard Apparatus, Holliston, MA) at the same (isovolemic-normovolemic) rate from the carotid artery catheter (4, 5, 19). This slow rate of exchange provided for a stable mean arterial pressure immediately after the exchange. Each animal was allowed a 10-min stabilization period before data acquisition.

Blood chemistry and biophysical properties. Arterial blood was collected in heparinized glass capillaries (0.05 ml) and immediately




Fig. 2. Hemodilution was attained by means of a progressive, stepwise, isovolemic blood exchange-transfusion protocol. Volume of each exchange-transfusion step was calculated as a percentage of the blood volume, estimated as 7% of body weight. An acute anemic state was induced by lowering systemic Hct, using a 5% recombinant human serum albumin (rHSA) solution, in 2 progressive steps of isovolemic hemodilution labeled level 1 and level 2 exchanges. Level 3 exchange was achieved by a third hemodilution that continued using rHSA or the vesicle solutions HbV₈ or HbV₂₉ suspended in 5% rHSA (test solutions). RBC, red blood cells.

analyzed for arterial PO₂ (PaO₂), arterial PCO₂ (PaCO₂), base excess (BE), and pH (Blood Chemistry Analyzer 248; Bayer, Norwood, MA). The comparatively low PaO₂ and high PaCO₂ values of these animals is a consequence of their adaptation to a fossorial environment. Blood samples for viscosity and colloid osmotic pressure measurements were quickly withdrawn from the animal with a heparinized 5-ml syringe at the end of the experiment for immediate analysis.

Viscosity was measured in a cone/plate viscometer (DV-II+) with a cone spindle (CPE-40; both from Brookfield Engineering Laboratories, Middleboro, MA) at a shear rate of 160 s⁻¹. Colloid osmotic pressure (COP) was measured using the Wescor 4420 colloid osmometer (23).

Functional capillary density. Functional capillary density (FCD; in cm⁻¹) is the total length of RBC-perfused capillaries divided by the area of the microscopic field of view (21). Capillary segments were considered functional if RBC were observed to transit over a 30-s period. FCD was tabulated from the capillary lengths with RBC flow in an area comprising 10 successive microscopic fields (420 × 320 μm). Detailed mappings were made of the chamber vasculature to study the same microvessels throughout the experiment.

Microhemodynamic parameters. Arteriolar and venular blood flow velocities were measured online using the photodiode cross-correlation technique (8) (Fiber Optic Photo Diode and Velocity Tracker Correlator model 102B; Vista Electronics, Ramona, CA). The centerline velocity (*V*) was corrected according to vessel size to obtain the mean RBC velocity (11). The video image shearing technique was used to measure vessel diameter (*D*) online. Blood flow was calculated from the measured parameters as $(Q) = V\pi(D/2)^2$.

Microvascular Po₂ distribution. High-resolution microvascular Po₂ measurements were made using phosphorescence-quenching microscopy (18), a method based on the oxygen-dependent quenching of phosphorescence emitted by albumin-bound metalloporphyrin complex after pulsed light excitation. Phosphorescence microscopy is not dependent on the level of dye within the tissue, and the decay time is inversely proportional to the Po₂ level. The phosphorescence decay curves were converted to oxygen tensions by using a fluorescence decay curve fitter (model 802; Vista Electronics) (9). This technique has been used in this animal preparation and others for both intravascular and extravascular oxygen tension measurements, because albumin exchange between plasma and tissue allows for sufficient concentrations of albumin-bound dye within the interstitium to achieve an adequate signal-to-noise ratio. Animals received a slow intravenous injection of 15 mg/kg body wt at a concentration of 10.1 mg/ml of a palladium-meso-tetra(4-carboxyphenyl)porphyrin (Porphyrin Products, Logan, UT). Po₂ measurements were made 20 min after porphyrin injection, allowing it to be distributed to all the tissues.

In our system, intravascular measurements are made by placing an optical rectangular window (5 × 40 μm) within the vessel of interest,

with the longest side of the rectangular slit positioned parallel to the vessel wall. Tissue Po₂ is measured in regions void of large vessels within intercapillary spaces with an optical window size of ~10 × 10 μm, which allows us to precisely establish the localization of the Po₂ measurements in arterioles, venules, and the interstitium (20). The phosphorescence decay due to quenching at a specific Po₂ yields a single decay constant, and in vitro calibration has been demonstrated to be valid for in vivo measurements. Intravascular and perivascular Po₂ measurements were made in the arterioles studied, and intravascular Po₂ measurements were made in venules. Interstitial tissue Po₂ was measured in regions distant from visible underlying and adjacent vessels.

Tissue oxygen delivery and extraction. The microvascular methodology used in our studies allows a detailed analysis of oxygen supply in the tissue. Calculations of O₂ delivery, defined as the amount of oxygen delivered by the arterioles to the microcirculation per unit time normalized relative to baseline, and O₂ extraction, defined as the amount of oxygen released by blood to the tissue by the microcirculation per unit time normalized relative to baseline, were made using Eqs. 1 and 2:

$$O_2 \text{ delivery} = \{(\text{RBC}_{\text{Hb}} \times \gamma \times \text{Sa}_{\text{RBC}}\%) + (\text{HbV}_{\text{Hb}} \times \gamma \times \text{Sa}_{\text{HbV}}\%) + (1 - \text{Hct}) \times \alpha \times \text{Pa}_{\text{O}_2}\} \times Q \quad (1)$$

$$O_2 \text{ extraction} = \{[\text{RBC}_{\text{Hb}} \times \gamma \times S(a - v)_{\text{RBC}}\%] + [\text{HbV}_{\text{Hb}} \times \gamma \times S(a - v)_{\text{HbV}}\%] + (1 - \text{Hct}) \times \alpha \times P(a - v)_{\text{O}_2}\} \times Q \quad (2)$$

where RBC_{Hb} is the [Hb] in RBC (expressed in g/dl of blood), HbV_{Hb} is the [Hb] in HbV (expressed in g/dl of blood), γ is the oxygen-carrying capacity of Hb at 100% saturation (or 1.34 ml O₂/g Hb), Sa% indicates the arteriolar oxygen saturation of RBC or HbV, S(a-v)% indicates the arteriovenous difference in oxygen saturation of RBC or HbV, (1 - Hct) is the fractional plasma volume (and converts the equation from units per dl of plasma to per dl of blood), α is the solubility of oxygen in plasma and is equal to 3.14 × 10⁻³ ml O₂/dl plasma mmHg, PaO₂ is the arteriolar partial pressure of oxygen, P(a-v)_{O₂} is the arteriovenous difference in Po₂, and Q is the microvascular flow for each microvessel as a percentage of baseline. The oxygen dissociation curves were determined as described before. In this analysis, microvascular Hct was corrected according to the findings of Lipowsky and Firrell (10).

Experimental procedure. Baseline systemic, microvascular, and hemodynamic characterizations were performed before the start of the exchange. After each exchange and a stabilization period of 10 min, systemic and/or microvascular measurements were performed. Exchanges began every hour. After the level 3 exchange transfusion, the same measurements were repeated, and then the Po₂ distribution was determined using phosphorescence-quenching microscopy (9). The duration of the experiment was 3–4 h.

Data analysis. Results are presented as means \pm SD unless otherwise noted. All data are presented as absolute values and ratios relative to baseline values. A ratio of 1.0 signifies no change from baseline, whereas lower and higher ratios are indicative of changes proportionally higher or lower than baseline. The same vessels and functional capillary fields were followed so that direct comparisons to their baseline levels could be performed, allowing for more robust statistics for small sample populations. For repeated measurements, time-related changes were assessed by analysis of variance (ANOVA). Data within each group were analyzed using ANOVA for nonparametric repeated measurement, and when appropriate, post hoc analyses were performed with the Dunn's multiple comparison tests. For level 3 exchange, groups were analyzed using one-way ANOVA, and post hoc analyses were performed with the Bonferroni post tests. All statistics were calculated using GraphPad Prism 4.01 (GraphPad Software, San Diego, CA). Changes were considered statistically significant if $P < 0.05$.

RESULTS

Exchange transfusion. Twenty-four animals (55–65 g body wt) entered into the exchange-transfusion (hemodilution) protocol, and all tolerated the experiment without any visible discomfort. Microvascular studies were completed in six preparations for each test material, namely, the level 2 rHSA, HbV₈, and HbV₂₉. The data were analyzed using a model for computing oxygen delivery to the tissue at the microscopic level.

Hematological changes. The exchange-transfusion protocol resulted in a final Hct ranging from 11.0 ± 0.5 to $11.4 \pm 0.6\%$. The HbV₈ and HbV₂₉ groups had a final plasma Hb concentration of 2.1 ± 0.1 g/dl, which increased the total Hb concentration in blood (RBC + Hb in plasma) to 5.7 ± 0.2 – 0.3 g/dl after completion of the level 3 exchange transfusion. Thus oxygen-carrying capacities at this level were similar to those found at level 2, where total blood Hb concentration was 5.7 ± 0.3 g/dl (Hct 18.1 ± 0.7) (Table 2).

Systemic and blood gas parameters. Changes in the systemic parameters are presented in Fig. 3. Mean arterial pressure was statistically lower for the extreme hemodilution tests with rHSA and the HbV₂₉ group and attained the highest value with HbV₈ viscosity. Heart rate after hemodilution followed by exchange transfusion with the HbV solutions was $\sim 10\%$ higher than baseline at the level 3 exchange. The slight increase in heart rate was not statistically different.




Fig. 3. Mean arterial blood pressure and heart rate [in beats/min (bpm)] at baseline (BL) (Hct 49%) and level 1 (Hct 29%), level 2 (Hct 18%), and level 3 (Hct, 11%) hemodilutions. Level 1 and level 2 exchanges were performed with 5% rHSA as diluent. Level 3 exchange was used to evaluate the oxygen transport of HbV₈ vs. HbV₂₉ and rHSA. † $P < 0.05$ relative to baseline; § $P < 0.05$ relative to level 3 rHSA; ¶ $P < 0.05$, level 3 with HbV₈ vs. level 3 with HbV₂₉.

Analysis of arterial blood gases (Table 2) showed a statistical increase in P_{O_2} after hemodilution and exchange transfusion. P_{aCO_2} was unchanged from baseline after hemodilution. Blood pH was not statistically changed. At level 3 exchange, BE was positive and not statistically different between HbV groups, but it was negative and statistically different from baseline for the rHSA group ($P < 0.05$).

Colligative properties. Blood viscosities and COP after level 3 exchange were sampled at 1 h and 10 min after completion

Table 2. Laboratory parameters during exchange protocol

	Baseline	Level 1 Hemodilution		Level 2 Hemodilution		Level 3 Hemodilution		
		rHSA	rHSA	rHSA	rHSA	HbV ₈	HbV ₂₉	
n	24	24	24	24	6	6	6	
Hct, %	48.8 ± 1.2	$28.8 \pm 0.8^*$	$18.1 \pm 0.7^*$	$11.1 \pm 0.8^*$	$11.0 \pm 0.5^*$	$11.4 \pm 0.6^*$		
Hb, g/dl								
Whole blood	14.8 ± 0.4	$9.0 \pm 0.5^*$	$5.7 \pm 0.3^*$	$3.7 \pm 0.4^*$	$5.7 \pm 0.2^{\dagger}$	$5.7 \pm 0.3^{\dagger}$		
Plasma					2.1 ± 0.1	2.1 ± 0.1		
P_{aO_2} , mmHg	59.2 ± 4.6	68.7 ± 5.2	$73.5 \pm 3.7^*$	$87.5 \pm 7.0^*$	$77.1 \pm 4.3^{\dagger}$	$76.4 \pm 4.4^{\dagger}$		
P_{aCO_2} , mmHg	49.2 ± 3.6	52.4 ± 6.7	49.0 ± 3.5	$42.0 \pm 3.2^*$	$53.0 \pm 3.9^{\dagger}$	46.8 ± 4.3		
Arterial pH	7.35 ± 0.02	7.35 ± 0.03	7.37 ± 0.03	7.38 ± 0.04	7.35 ± 0.03	7.36 ± 0.03		
HCO_3^- , mM	27.9 ± 2.3	28.5 ± 3.5	27.6 ± 2.2	24.8 ± 2.5	28.2 ± 2.6	25.8 ± 2.1		
BE, mM	3.2 ± 2.0	3.4 ± 2.4	2.9 ± 2.1	$-0.2 \pm 1.9^*$	$3.1 \pm 1.7^{\dagger}$	1.0 ± 2.0		

Values are means \pm SD. Baseline values include all animals in the study. No significant differences were detected between the baseline values of each group or between the values after level 1 and level 2 exchange before the exchange with test solutions. Hct, systemic hematocrit; Hb, hemoglobin content of blood; P_{aO_2} , arterial partial O₂ pressure; P_{aCO_2} , arterial partial pressure of CO₂; BE, base excess. * $P < 0.05$ compared with baseline; † $P < 0.05$ compared with level 3 rHSA; ‡ $P < 0.05$ compared with level 3 HbV₈ to level 3 HbV₂₉.

Table 3. Rheological properties and COP

Fluid	Blood Viscosity, cp	Plasma Viscosity, cp	COP, mmHg	n
Blood	4.2±0.7	1.2±0.1	17.6±0.7	6
Level 2 rHSA	2.0±0.2*	0.9±0.1	17.2±0.8	4
Level 3 rHSA	1.6±0.2*	0.9±0.1	17.4±1.1	5
Level 3 HbV ₈	1.9±0.3*	1.0±0.1	17.3±0.8	6
Level 3 HbV ₂₉	2.0±0.4*	1.0±0.1	17.8±1.0	5

Values are means ± SD; n = no. of animals studied. Viscosity was measured at a shear rate of 160 s⁻¹ at 37°C. COP was measured at 27°C. Hct are presented in Table 2. *P < 0.05 compared with nondiluted blood.

of the exchange. Table 3 shows that blood viscosity ranges from 1.6 cp (plasma 0.9 cp) for rHSA to 2.0 cp (plasma 1.0 cp) for the HbV groups.

All test materials caused COP to maintain the value for normal blood for this species (5), namely, 17.6 ± 0.7 mmHg at 1 h after the last exchange, showing that introduction of bulk solutions into the circulation caused minor fluid shifts.

Microhemodynamics. After level 3 exchange, arteriolar and venular diameters were not statistically different from baseline for any of the groups. Arteriolar flow velocities attained the highest value for the HbV₈ group, being 1.90 relative to baseline, which was statistically significant. The same effect was found in the venular microcirculation, where blood flow velocity was 2.20 relative to baseline. HbV₂₉ exchange transfusion lowered both arteriolar and venular velocities relative to the values attained at the level 2 exchange. However, venular velocity in this group was statistically significantly higher than in baseline. Notably, the level 2 hemodilution with rHSA caused significantly higher blood flow velocities in the arteriolar and venular microcirculation (Fig. 4).

Combining data for the RBC flow velocity and diameter allowed calculation of the arteriolar and venular blood flows (Fig. 5). The results of this calculation showed that all exchanges caused blood flow to increase. Arteriolar and venular blood flows at level 2 exchange with the use of rHSA were

significantly higher than those at baseline. However, continuing hemodilution with this material to level 3 exchange did not sustain the increase, and arteriolar and venular blood flow, although showing a tendency to remain elevated, were not statistically different from baseline values.

Level 3 exchange transfusion with HbV₈ and HbV₂₉ caused blood flow to be significantly higher than baseline. Furthermore, the HbV₈ group showed consistently higher blood flows than the HbV₂₉ group; however, the trend was not statistically significant.

Functional capillary density. The number of capillaries with RBC passage upon level 3 hemodilution in the rHSA, HbV₈, and HbV₂₉ groups was 62 ± 9, 76 ± 12, and 72 ± 13% of baseline, respectively. These values were statistically different from baseline but not statistically different with respect to each other (Fig. 6).

Microvascular oxygen distribution. Oxygen tension measured using phosphorescence microscopy after level 3 exchange transfusion in the rHSA, HbV₈, and HbV₂₉ groups showed that these materials produced virtually identical distributions of arteriolar microvascular Po₂ (arterioles averaged 49.5 mmHg), although HbV₈ tended to be higher (Fig. 7). The decrease of RBC from level 2 to level 3 did not decrease the arteriolar Po₂. Venular Po₂ after level 3 was significantly lower than at level 2 exchange in all cases (rHSA, 7.2 ± 3.2 mmHg; HbV₈, 15.1 ± 3.7 mmHg; HbV₂₉, 9.6 ± 4.2 mmHg).

Tissue Po₂ values at level 3 exchange were consistently lower than those at level 2 exchange (20.1 ± 2.2 mmHg), with the difference being statistically significant. The highest was attained by the HbV₈ group, being 14.0 ± 2.2 mmHg. By comparison, tissue Po₂ for the HbV₂₉ group was 9.2 ± 2.7 mmHg and for the rHSA group, 2.6 ± 1.4 mmHg, which was significantly lower compared with the HbV₈ and HbV₂₉ groups (Fig. 7).

Oxygen delivery and extraction. Figure 8 shows the results of the analysis for delivery and release of oxygen by the





Fig. 4. Changes relative to baseline in arteriolar and venular hemodynamics at the level 1, level 2, and level 3 exchanges. Dashed lines represent baseline level. †P < 0.05 relative to baseline. Arteriolar (A) and venular (B) diameters (μm, means ± SD, n = no. of vessels studied) in each animal group were as follows. Baseline: arterioles (A), 61.2 ± 10.2, n = 80; venules (V), 62.0 ± 12.3, n = 80. Level 1 with rHSA: A, 65.6 ± 12.4; V, 61.1 ± 12.4. Level 2 with rHSA: A, 66.1 ± 14.6; V, 64.3 ± 15.2. Level 3 with rHSA: A, 63.7 ± 14.4, n = 20; V, 61.0 ± 16.7, n = 20. Level 3 with HbV₈: A, 64.9 ± 15.7, n = 20; V, 64.6 ± 18.2, n = 20. Level 3 with HbV₂₉: A, 66.1 ± 16.2, n = 20; V, 63.1 ± 18.0, n = 20. Arteriolar (C) and venular (D) RBC velocities (mm/s, means ± SD) in each animal group were as follows. Baseline: A, 4.9 ± 1.3; V, 1.7 ± 0.5. Level 1 with rHSA: A, 6.3 ± 1.4; V, 2.0 ± 0.7. Level 2 with rHSA: A, 7.9 ± 1.5; V, 2.6 ± 0.9. Level 3 rHSA: A, 5.2 ± 2.0, n = 20; V, 1.9 ± 1.1, n = 20. Level 3 with HbV₈: A, 7.2 ± 1.8, n = 20; V, 3.3 ± 1.0, n = 20. Level 3 with HbV₂₉: A, 7.0 ± 1.7, n = 20; V, 3.0 ± 0.9, n = 20.

Fig. 5. Arteriolar and venular flow (nl/s, means \pm SD, *n* = no. of vessels studied) in each animal group were as follows. Baseline: arterioles (A), 14.8 ± 7.1 , *n* = 76; venules (V), 5.0 ± 2.9 , *n* = 76. Level 1 with rHSA: A, 21.9 ± 9.7 ; V, 5.8 ± 3.6 . Level 2 with rHSA: A, 27.2 ± 16.1 ; V, 8.3 ± 4.2 . Level 3 with rHSA: A, 16.9 ± 6.8 , *n* = 20; V, 5.4 ± 4.8 , *n* = 20. Level 3 with HbV₈: A, 23.4 ± 8.1 , *n* = 18; V, 9.9 ± 5.1 , *n* = 18. Level 3 with HbV₂₉: A, 21.0 ± 8.0 , *n* = 18; V, 8.3 ± 5.2 , *n* = 18.



microcirculation. It is apparent that exchanging RBC for HbV₈ maintains oxygen delivery to the tissue, whereas HbV₂₉ reduces this by ~20%, and continued hemodilution with a non-oxygen-carrying material significantly depresses oxygen delivery to the tissue, reducing this to half of that attained at the level 2 hemodilution.

DISCUSSION

The principal finding of this study is that under identical extreme hemodilution conditions, with the use of vesicles encapsulating Hb with normal P₅₀ (HbV₂₉ = 29 mmHg) and low P₅₀ (HbV₈ = 8 mmHg), tissue P_{O₂} is statistically significantly higher when the high oxygen affinity material is used, namely, 14.0 ± 2.2 vs. 9.2 ± 2.7 mmHg. The significantly increased tissue P_{O₂} attained with HbV₈ appears to be due to a series of incremental improvements in microvascular and macrovascular hemodynamics comprising the increase of arteriolar blood flow and mean arterial blood pressure, which was significantly higher (*P* < 0.05) for HbV₈ than for HbV₂₉.

In the hemodilution procedures of this study, blood was exchanged with a rHSA solution as a colloidal plasma expander, which was the same suspending medium used for the Hb vesicles. Therefore, in these experiments, we can make a direct comparison between an oxygen-carrying and non-oxy-

gen-carrying blood substitute, uncomplicated by the presence of additional materials. Our results show that the level 2 hemodilution with rHSA leads to maintained functional capillary density and significantly improved arteriolar and venular blood flow, although somewhat lowered central blood pressure. The latter finding is not necessarily negative and may reflect a lowered overall peripheral vascular resistance due to the decrease of blood viscosity after hemodilution. The fact that microvascular flow is significantly increased indicates that the level 2 hemodilution with rHSA provides the tissue with adequate microvascular perfusion and that this colloid is an adequate plasma expander.

Average oxygen delivery and extraction were somewhat greater for HbV₈ than for HbV₂₉. These are calculated values and are not statistically significantly different; however, the same difference was found in all micro and macro parameters measured in this study.

The level 2 hemodilution and the succeeding level 3 hemodilution with either HbV₈ and HbV₂₉ resulted in the same total Hb concentration in the circulation (5.7 and 5.8 g Hb/dl); however, oxygen delivery was lower with HbV₂₉ and lowest with rHSA, as might be expected due to the low Hb content (3.7 g Hb/dl) in the absence of plasma Hb for the rHSA group. Therefore, because all groups had the same Hct at the level 3 hemodilution, the sustained oxygen consumption and tissue P_{O₂} relative to the rHSA group clearly demonstrate that Hb vesicles release oxygen. However, the vesicles with the lowest P₅₀ provide an oxygen delivery capacity identical to that of blood at level 2 hemodilution, whereas vesicles with a high P₅₀ lower oxygen delivery at the microcirculatory level, an effect probably caused by the decreased blood flow associated with HbV₂₉.

The differences in tissue P_{O₂}, mean arterial blood pressure, and arteriolar blood flow between HbV₈ and HbV₂₉ show that in designing a blood substitute, it is not sufficient to provide adequate oxygen-carrying capacity. Once a suitable oxygen carrier is available, it also must be able to maintain or enhance other circulatory transport parameters, particularly flow. The Hb vesicles used in this study are vasoinactive, and the difference in P₅₀ appears to be a factor in improving flow condition that is not related to vasoactivity. An explanation for this may be related to the inherent variability of tissue P_{O₂} shown in this and other studies (4, 22), which may be enhanced in extreme hemodilution. This variability determines that if average tissue P_{O₂} is low, portions of the tissue may become anoxic. Introducing a small quantity of a low-P₅₀ Hb oxygen carrier into the circulation will deliver oxygen only to those parts of the tissue




Fig. 6. Functional capillary density after the level 1, level 2, and level 3 exchanges for the different test fluids. All values are relative to baseline levels. †*P* < 0.05 relative to baseline.




Fig. 7. Intravascular PO₂ after the level 2 and level 3 hemodilutions. Values are presented as means \pm SD. ‡*P* < 0.05 compared with level 2 with rHSA; §*P* < 0.05 compared with level 3 with rHSA; ¶*P* < 0.05, level 3 with HbV₈ vs. level 3 with HbV₂₉.

where the anoxic threshold is passed, thus eliminating the inherent variability of oxygen delivery shown by the variability of tissue PO₂.

Considering the significantly improved blood pressure and the trend toward higher flow for HbV₈ (in the absence of vasoconstriction and changes in the rheological properties of blood), it is possible that in conditions of extreme hemodilution the cardiac function should be improved because of the proposed more homogenous heart tissue oxygenation using HbV₈ vs. HbV₂₉.

In summary, the present results show that either HbV₈ or HbV₂₉ are efficient oxygen carriers that do not cause vasoactivity. The experiments were carried out using rHSA as a hemodiluent, and this material was adequate as a plasma volume substitute. Oxygen extraction was similar for both oxygen carriers; however, HbV₈ appeared to be beneficial at the systemic level, because base excess remained at baseline levels, whereas it was decreased for HbV₂₉. This finding suggests that improved tissue PO₂ and microcirculatory oxygen delivery may be efficient in other tissues. The improvement obtained may be specific to the conditions of these experiments

in which the vesicles were tested for their capacity to restore tissue PO₂, FCD, and oxygen extraction in the microcirculation during extreme hemodilution. The significant differences in the tissue oxygen parameters produced by the presence of low-P₅₀ Hbs vs. an identical oxygen carrier with normal P₅₀ suggests that small amounts of Hbs with high oxygen affinity may have therapeutic effects in the treatment of ischemic conditions (6).

ACKNOWLEDGMENTS

We greatly acknowledge A. Barra and C. Walter (Univ. of California-San Diego) for technical assistance and Drs. K. Sou and Y. Teramura (Waseda University) for preparation of the HbV suspension.

GRANTS

This work was supported by National Heart, Lung, and Blood Institute (NHLBI) Bioengineering Research Partnership Grant R24-HL-64395, NHLBI Grants R01-HL-62354 and R01-HL-62318 (to M. Intaglietta), and NHLBI Program Project Grant P01-HL-71064-01 (to Dr. J. Friedman) and by U.S. Army Grant PR023085, Health Sciences Research Grants (Research on Regulatory Science), the Ministry of Health, Labour, and Welfare, Japan, and grants in aid for Scientific Research from the Japan Society for the Promotion of Science (B16300162).




Fig. 8. Arterial oxygen delivery (DO₂) and extraction (VO₂) before and after the level 3 hemodilution. Calculations of global oxygen transport are not directly measurable in our model; however, the changes relative to baseline can be calculated using the measured parameters. These calculations can be identified as those presented without standard deviations to focus on their tendencies rather than on the variability of the measurement.

REFERENCES

1. Altman DG and Bland JM. Statistics notes: how to randomise. *BMJ* 319: 703–704, 1999.
2. Baines AD and Drangova R. Does dopamine use several signal pathways to inhibit Na-Pi transport in OK cells? *J Am Soc Nephrol* 9: 1604–1612, 1998.
3. Baines AD and Ho P. O₂ affinity of cross-linked hemoglobins modifies O₂ metabolism in proximal tubules. *J Appl Physiol* 95: 563–570, 2003.
4. Cabrales P, Kanika ND, Manjula BN, Tsai AG, Acharya SA, and Intaglietta M. Microvascular PO₂ during extreme hemodilution with hemoglobin site specifically PEGylated at Cys-93(B) in hamster window chamber. *Am J Physiol Heart Circ Physiol* 287: H1609–H1617, 2004.
5. Cabrales P, Tsai AG, and Intaglietta M. Microvascular pressure and functional capillary density in extreme hemodilution with low and high plasma viscosity expanders. *Am J Physiol Heart Circ Physiol* 287: H363–H373, 2004.
6. Endrich B, Asaishi K, Götz A, and Messmer K. Technical report: a new chamber technique for microvascular studies in unanaesthetized hamsters. *Res Exp Med (Berl)* 177: 125–134, 1980.
7. Hogan MC, Bebout DE, and Wagner PD. Effect of increased Hb-O₂ affinity on $\dot{V}O_{2\max}$ at constant O₂ delivery in dog muscle in situ. *J Appl Physiol* 70: 2656–2662, 1991.
8. Intaglietta M, Silverman NR, and Tompkins WR. Capillary flow velocity measurements in vivo and in situ by television methods. *Microvasc Res* 10: 165–179, 1975.
9. Kerger H, Groth G, Kalenka A, Vajkoczy P, Tsai AG, and Intaglietta M. pO₂ measurements by phosphorescence quenching: characteristics and applications of an automated system. *Microvasc Res* 65: 32–38, 2003.
10. Lipowsky HH and Firrell JC. Microvascular hemodynamics during systemic hemodilution and hemoconcentration. *Am J Physiol Heart Circ Physiol* 250: H908–H922, 1986.
11. Lipowsky HH and Zweifach BW. Application of the “two-slit” photometric technique to the measurement of microvascular volumetric flow rates. *Microvasc Res* 15: 93–101, 1978.
12. Sakai H, Hara H, Yuasa M, Tsai AG, Takeoka S, Tsuchida E, and Intaglietta M. Molecular dimensions of Hb-based O₂ carriers determine constriction of resistance arteries and hypertension. *Am J Physiol Heart Circ Physiol* 279: H908–H915, 2000.
13. Sakai H, Masada Y, Horinouchi H, Yamamoto M, Ikeda E, Takeoka S, Kobayashi K, and Tsuchida E. Hemoglobin-vesicles suspended in recombinant human serum albumin for resuscitation from hemorrhagic shock in anesthetized rats. *Crit Care Med* 32: 539–545, 2004.
14. Sakai H, Tomiyama KI, Sou K, Takeoka S, and Tsuchida E. Polyethyleneglycol-conjugation and deoxygenation enable long-term preservation of hemoglobin-vesicles as oxygen carriers in a liquid state. *Bioconjug Chem* 11: 425–432, 2000.
15. Sakai H, Tsai AG, Intaglietta M, and Tsuchida E. Hemoglobin encapsulation with polyethylene glycol-modified and unmodified vesicles: systemic and microvascular hemodynamics at 80% blood substitution. In: *Advances in Blood Substitutes. Industrial Opportunities and Medical Challenges*, edited by Winslow RM, Vandegriff KD, and Intaglietta M. Boston, MA: Birkhäuser, 1997, p. 151–166.
16. Sakai H, Tsai AG, Rohlfis RJ, Hara H, Takeoka S, Tsuchida E, and Intaglietta M. Microvascular responses to hemodilution with Hb vesicles as RBC substitutes: influence of O₂ affinity. *Am J Physiol Heart Circ Physiol* 276: H553–H562, 1999.
17. Sou K, Endo T, Takeoka S, and Tsuchida E. Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles. *Bioconjug Chem* 11: 372–379, 2000.
18. Torres Filho IP and Intaglietta M. Microvessel PO₂ measurements by phosphorescence decay method. *Am J Physiol Heart Circ Physiol* 265: H1434–H1438, 1993.
19. Tsai AG. Influence of cell-free hemoglobin on local tissue perfusion and oxygenation after acute anemia after isovolemic hemodilution. *Transfusion* 41: 1290–1298, 2001.
20. Tsai AG, Friesenecker B, Mazzoni MC, Kerger H, Buerk DG, Johnson PC, and Intaglietta M. Microvascular and tissue oxygen gradients in the rat mesentery. *Proc Natl Acad Sci USA* 95: 6590–6595, 1998.
21. Tsai AG, Friesenecker B, McCarthy M, Sakai H, and Intaglietta M. Plasma viscosity regulates capillary perfusion during extreme hemodilution in hamster skin fold model. *Am J Physiol Heart Circ Physiol* 275: H2170–H2180, 1998.
22. Tsai AG, Vandegriff KD, Intaglietta M, and Winslow RM. Targeted O₂ delivery by low-P₅₀ hemoglobin: a new basis for O₂ therapeutics. *Am J Physiol Heart Circ Physiol* 285: H1411–H1419, 2003.
23. Webb AR, Barclay SA, and Bennett ED. In vitro colloid osmotic pressure of commonly used plasma expanders and substitutes: a study of the diffusibility of colloid molecules. *Intensive Care Med* 15: 116–120, 1989.

Reduction of Methemoglobin via Electron Transfer from Photoreduced Flavin: Restoration of O₂-Binding of Concentrated Hemoglobin Solution Coencapsulated in Phospholipid Vesicles

Hiroshi Sakai, Yohei Masada, Hiroto Onuma, Shinji Takeoka, and Eishun Tsuchida*

Advanced Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan. Received April 9, 2004; Revised Manuscript Received July 31, 2004

Ferric methemoglobin is reduced to its ferrous form by photoirradiation either by direct photoexcitation of the heme portion to induce electron transfer from the surrounding media (Sakai et al. (2000) *Biochemistry* 39, 14595–14602) or by an indirect electron transfer from a photochemically reduced electron mediator such as flavin. In this research, we studied the mechanism and optimal condition that facilitates photoreduction of flavin mononucleotide (FMN) to FMNH₂ by irradiation of visible light, and the succeeding reduction of concentrated metHb in phospholipid vesicles to restore its O₂ binding ability. Visible light irradiation (435 nm) of a metHb solution containing FMN and an electron donor such as EDTA showed a significantly fast reduction to ferrous Hb with a quantum yield (Φ) of 0.17, that is higher than the method of direct photoexcitation of heme ($\Phi = 0.006$). Electron transfer from a donor molecule to metHb via FMN was completed within 30 ns. Native-PAGE and IEF electrophoresis indicated no chemical modification of the surface of the reduced Hb. Coencapsulation of concentrated Hb solution (35 g/dL) and the FMN/EDTA system in vesicles covered with a phospholipid bilayer membrane (Hb-vesicles, HbV, diameter: 250 nm) facilitated the metHb photoreduction even under aerobic conditions, and the reduced HbV restored the reversible O₂ binding property. A concentrated HbV suspension ([Hb] = 8 g/dL) was sandwiched with two glass plates to form a liquid layer with the thickness of about 10 μ m (close to capillary diameter in tissue, 5 μ m), and visible light irradiation (221 mW/cm²) completed 100% metHb photoreduction within 20 s. The photoreduced FMNH₂ reacted with O₂ to produce H₂O₂, which was detected by the fluorescence measurement of the reaction of H₂O₂ and *p*-nitrophenylacetic acid. However, the amount of H₂O₂ generated during the photoreduction of HbV was significantly reduced in comparison with the homogeneous Hb solution, indicating that the photoreduced FMNH₂ was effectively consumed during the metHb reduction in a highly concentrated condition inside the HbV nanoparticles.

INTRODUCTION

Photoinduced electron transfer is an essential reaction in biological systems especially during photosynthesis by the chlorophyll–protein complex (1). Hemoproteins such as hemoglobin (Hb) and myoglobin (Mb) are originally not related to the photoreaction in a biological system; however, photoexcitation and the resulting electron transfer reactions have been extensively studied (2–6). In our previous report, we clarified the mechanism of reduction of ferric methemoglobin (metHb) to its ferrous form by the direct excitation of the porphyrin N band in the UVA region (7). The reduction proceeds by charge transfer from the porphyrin ring to the central ferric iron to form the porphyrin π cation radical and ferrous iron by the N band excitation, and the contribution of the amino acid residues in the globin chain as an electron donor or an electron pathway. Another photochemical process to reduce metHb is an electron transfer from photochemically reduced flavin derivatives. The precise photoreduction mechanism of a flavin derivative to its reduced form has been extensively studied (8–10), and this has contributed to the understanding of the mechanism of the electron transfer of flavoproteins (11–17) and their function in the biological systems such as bacterial photosynthesis (18) and visual organs (19).

Irrespective of the flavoproteins, the photoreduction of metMb and metHb by the externally added photoreduced form of the flavin mononucleotide (FMN) was first reported by Brwon and Synder (20) and Yubisui et al. (21, 22), respectively.

We have paid special attention to the reduction of hemoproteins that will be applicable to Hb-based artificial red cells (23). We focus on the liposome-encapsulated Hb; a concentrated Hb solution is encapsulated in phospholipid vesicles to form Hb-vesicles (HbV)¹ with a particle size of about 250 nm (24, 25). Ferrous state Hb binds oxygen to form HbO₂; however, it gradually converts to ferric metHb and superoxide anion and loses its oxygen binding property both in vivo and in vitro (26). A series of thiols was studied as a reductant for metHb,

¹ Abbreviations: HbV, Hb-vesicles; FMN, flavin mononucleotide; SOD, superoxide dismutase; EDTA, ethylenediamine tetraacetic acid; DTPA, diethylenetriamine pentaacetic acid; IEF, isoelectric focusing; Native-PAGE, Native-polyacrylamide gel electrophoresis; PEG, poly(ethylene glycol); DPPC, 1,2-dipalmitoyl-*sn*-glycero-3-phosphatidylcholine; DHSG, 1,5-*O*-dihexadecyl-*N*-succinyl-L-glutamate; PEG-DSPE, 1,2-distearoyl-*sn*-glycero-3-phosphatidylethanolamine-*N*-PEG₅₀₀₀; HbCO, carbonylhemoglobin; [FMN]_{in}, concentration of FMN in HbV; [EDTA]_{in}, concentration of EDTA in HbV; [heme]_{in}, concentration of heme in HbV; PHA, *p*-hydroxyphenylacetic acid; DBDA, 6,6'-dihydroxy-(1,1'-biphenyl)-3,3'-diacetic acid, FMN*, triplet FMN; FMNH₂, reduced form of FMN;

* To whom correspondence should be addressed. Phone, +81-3-5286-3120; Fax, +81-3-3205-4740; e-mail, eishun@waseda.jp.